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ABSTRACT
Due to the increased consumption of unhealthy foods rich in sugar and fat along with a
highly sedentary lifestyle the prevalence of obesity has steadily increased in the United
States and the rest of the world. In America about one third of the adult population is obese
putting them at a greater risk for diseases such as cancer, cardio-vascular disorders,
inflammation and metabolic diseases such as diabetes and non-alcoholic fatty liver disease
(NAFLD). NAFLD can be classified into two major categories non-alcoholic fatty liver
(NAFL) and non-alcoholic steato-hepatitis depending on the extent of damage which
ranges from simple fat accumulation (steatosis) to fibrosis and cirrhosis. The major
concern with this disease is that it is largely asymptomatic. About 25% of adult Americans
have a fatty liver. High fat diet and common environmental pollutants such as
trihalomethanes can act as an important predisposition for the progression of NAFLD.
Although there have been reports of fatty liver and intestinal inflammation and
carcinogenesis, the exact mechanism for this process remains largely elusive. In this study,
I looked at the mechanisms of the cation channel Purinergenic receptor X7 (P2X7r) in liver
inflammation and fibrosis and subsequent ectopic crosstalk between the liver and the
intestines. Bromo-dichloromethane (BDCM) metabolism in the liver hepatocytes activated
P2X7r channels in the hepatic stellate cells inducing GLUT4 expression and translocation
leading to increased intracellular glucose levels via AKT phosphorylation. Increased
glucose consumption activated the stellate cells causing extensive fibrosis and scarring.
v

Simultaneously the liver resident macrophages (Kupffer cells) underwent pyroptosis by
NLRP3 inflammasome assembly releasing damage associated molecular patterns
(DAMP’s) such as High mobility group box 1 (HMGB1) into circulation. HMGB1 thus
released could bind to and activate receptor for advanced glycation end products (RAGE)
in the intestines. Activated RAGE in-turn could recruit the NADPH oxidase enzyme
complex at the cell membrane generating peroxynitrite in association with the nitric oxide
synthase. Peroxynitrite could recruit Toll like receptor 4 (TLR-4) to the lipid rafts via AKT
phosphorylation. Upon membrane recruitment TLR-4 could itself bind to excess HMGB1
in circulation leading to inflammation by TLR4 signaling. Thus, this study sheds new light
on a mechanism of cross talk between two organ systems and opens new avenues to use
therapeutic interventions for liver fibrosis and ectopic inflammation.
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CHAPTER 1
INTRODUCTION
Obesity is a worldwide pandemic. Over the last decade due to consumption of unhealthy
diet and increasingly sedentary lifestyle the number of obese individuals has increased
tremendously across the world. In the U.S. alone more than one third of the adult population
is obese(1). Built environment and Socio-economic status has played a critical role in the
rise of obese patients in the U.S. Obesity is associated with a myriad of health
complications such as hypertension, coronary heart diseases, stroke, sleep apnea, cancer
and metabolic diseases such as type 2 diabetes and non-alcoholic fatty disease (2, 3).
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease in the world due to the rising levels of obesity and metabolic disorders (4). NAFLD
is described as the over accumulation of lipids (>5%) in the liver which is not brought
about by the consumption of alcohol (1). The prevalence of NAFLD in the U.S. is between
20- 30%, and 80-90% of obese adults, 30-50% in patients with diabetes and up to 90% in
patients having hyperlipidemia. In children, the prevalence of NAFLD is 3-10% rising up
to 40-90% in obese children (5). NAFLD is categorized depending on the underlying
histological characteristics from simple fat accumulation (steatosis) known as a fatty liver
to inflammation and fibrosis forming scar tissue a state known as non-alcoholic
steatohepatitis (NASH). Most patients largely go undetected as the disease is asymptomatic
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and patients feel fine until they develop irreversible liver damage (6). Obesity is associated
with elevated circulating levels of pro inflammatory factors such as hormones and
cytokines such as Tumor necrosis factor (TNF-α), Interleukin 1 (IL-1) and Interleukin 6
(IL-6) (7). Insulin resistance (IR) plays an important role in aggravating this process by
decreasing insulin dependent lipolysis, increasing the levels of free fatty acids (FFA).
Leptin is a hormone released by the adipocytes that can act as a cytokine, it is the satiety
hormone that regulates the levels of stored fat. NAFLD is associated with leptin resistance
(8). Increased circulatory leptin increases inflammation and activates hepatic stellate cells
resulting in fibrosis and scarring (9).
According to the multiple hit theory, a steatotic liver is more prone to secondary
assaults such as gut bacteria, redox stress, mitochondrial dysfunction, environmental
pollutants, etc (10). Air particulate matter < 2.5µm size, mainly constituted by organic and
elemental carbon, sulfates and nitrates which are the common air pollutants has shown to
work synergistically with high fat diet to induce metabolic syndrome (11). Mice exposed
to similar size of air particulate matter for extended periods showed increased
inflammation, hepatic lipid accumulation, increased plasma tri-glycerides, low/very lowdensity lipoproteins (LDL/VLDL), reduced glycogen storage indicating an altered glucose
metabolism. Studies by Zheng et al showed that although a short exposure to atmospheric
levels of these air pollutants only caused low grade liver inflammation however when this
exposure was prolonged, it activated hepatic Kufpper cells, inducing an inflammatory
response. This is mediated through c-Jun N-terminal Kinases (JNKs)-activator protein 1
(AP1), nuclear factor-κB (NF-κB) and Toll-like receptor 4 (TLR4) activation. Along with
the activation of various inflammatory signaling pathways, there is deregulation of
2

peroxisome proliferator-activated receptors (PPAR’s) (12). PPAR’s are mainly responsible
for maintenance of fatty acid oxidation, anti-inflammatory responses and and maintaining
lipid and glucose homeostasis in Kupffer cells, hepatocytes and the hepatic stellate cells
(13). Another class of compounds known as dioxins commonly formed during incarnation
of industrial and domestic waste are also able to induce steato-hepatitis (14). The liver
plays a major role in detoxification of many drugs, hormones and environmental toxins in
contaminated water and food. Pesticides, heavy metals, trihalomethanes and many others
are detected in water sources and/or in food which are known to cause NAFLD and NASH
(15). Trihalomethanes (THMs) are short lived halogenated compounds which are formed
when

disinfectants

such

as

chlorine

interact

with

natural

organic

matter.

Bromodichloromethane (BDCM), trichloromethane (TCM), dibromochloromethane
(DBCM) and tribromomethane (TBM) are four THMs commonly found in chlorinated
water and humans are exposed to them through ingestion, inhalation and direct contact as
THMs may enter human body through drinking water, showering, swimming, etc (16).
Since the liver is metabolizes most of the xenobiotic compounds absorbed by the gastrointestinal tract it is the primary site for THM exposure. Previous reports from our lab show
that low acute exposure of Brono-dichloro methane (BDCM) in high fat diet fed mice
generated oxidative stress mediated by CY2E1 metabolism in the liver. Increased hepatic
leptin due to prevalent obese conditions along with BDCM induced oxidative stress
augmented hepatic inflammation, activated Kupffer cells, hepatic stellate cells leading to
fibrogenesis and NASH progression. BDCM treated mice also show a dysregulation of
glycolytic pathways and an increase glucose transport resulting in dyslipidemia and NASH
development (17-19). Several reports suggest increased levels of free glucose result in
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activating hepatic stellate cells leading to hepatic injury and scarring (20, 21). Purinergic
receptor X7 (P2X7r) is a cation gated ion channel that is a key modulator in liver fibrosis
and inflammation (22). P2X7r can activate hepatic stellate cells in progressive NAFLD
(23), In the second chapter of this thesis, I explored the mechanisms by which P2X7r is
able to increase glucose consumption in hepatic stellate cells thereby activating them by
inducing and translocating GLUT4 to cell surface (24).
Liver resident macrophages (Kupffer cells) constitute about 80-90% of all tissue
macrophages in the body (25). Kupffer cells are central to innate immunity and rapidly
recognize potential danger from various endogenous and exogenous sources to undergo
activation. Activated Kupffer cells interact with hepatocytes and other cells by release of
various cytokines, chemokines, Damage associated molecular patterns (DAMP’s) (26)
Pathogen associated molecular patterns (PAMP’s) such as lipopolysaccharides (LPS) on
bacterial cell surface can also trigger Kupffer cell activation due to increased permeability
of the intestinal barrier in NAFLD (27, 28). P2X7r is up-regulated in response to LPS and
endogenous ATP (29). Though there are reports of P2X7r and liver injury in
acetaminophen hepatoxicity and Carbon-tetrachloride mediated NASH (30, 31), the
involvement of P2X7r of Kupffer cells is not well studied. In the third chapter, I show that
P2X7r activation by LPS and ATP can induce the NLRP3 inflammasome leading to release
of High mobility group box 1 (HMGB1) protein via pyroptosis a unique form of cell death,
dependent on the activation of Caspase 1 and release of cytokines IL-1β and IL-18 (32) in
Kupffer cells.
HMGB1 is a chromatin binding protein which interacts with the nucleosome,
transcription factors and histones (33). HMGB1 binds to a distorts DNA facilitating the
4

binding of other proteins. HMGB1 is now considered as a cytokine because it is secreted
by activated macrophages, activating inflammatory responses in immune and endothelial
cells and transduces cellular signals by binding to cell surface receptors such as receptor
for advanced glycation end products (RAGE) and toll like receptors TLR2 and TLR4.
Activated macrophages secrete HMGB1 as a delayed mediator of inflammation (34).
Downstream signaling by binding to either RAGE or TLR4 leads to NFκB activation
releasing inflammatory cytokines such as IL-1β and IL-6 (35). Interestingly NADPH
oxidase (NOX2) activation produces peroxynitrite which recruits TLR-4 to the lipid rafts
enhancing TLR4 signaling and cytokine release (36). In my fourth chapter, I have shown
that endogenous HMGB1 selectively binds to and activates RAGE receptors in the
intestines. Activated RAGE receptor can recruit the subunits of NOX2; p47Phox to the cell
membrane activating it. Activated NOX2 then forms peroxynitrite recruiting TLR-4 to the
cell membrane where it can further bind to HMGB1 or exogenous LPS, leading to
downstream inflammatory signaling cascade. The liver is known as the secondary
metastatic site for colon carcinoma however there are very few reports exploring the ability
of a diseased liver to communicate and affect distant organs such as the intestines. Thus,
my research provides a novel mechanism showing the effects of a fatty liver on other
organs in obese individuals. Identifying HMGB1 as a key cytokine in ectopic inflammation
in NAFLD can help in development of novel therapeutics such as use of HMGB1
antibodies along with antagonists /inhibitors for TLR-4 and RAGE for management and
control of NAFLD progression.
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CHAPTER 2
PURINERGIC RECEPTOR X7 MEDIATES LEPTIN INDUCED GLUT4
FUNCTION IN STELLATE CELLS IN NON-ALCOHOLIC
STEATOHEPATITIS1

1

Chandrashekaran V, Das S, Seth RK, Dattaroy D, Alhasson F, Michelotti GA,
Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Purinergic receptor X7 mediates
leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim
Biophys Acta 1862 (1): 32-45, 2016.
Reprinted here with the permission of the publisher.
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Abstract:
Metabolic oxidative stress via CYP2E1 can act as a second hit in NASH progression. Our
previous studies have shown that oxidative stress in NASH causes higher leptin levels and
induces purinergic receptor X7 (P2X7r). We tested the hypothesis that higher circulating
leptin due to CYP2E1-mediated oxidative stress induces P2X7r. P2X7r in turn activates
stellate cells and causes increased proliferation via modulating Glut4, the glucose
transporter, and increased intracellular glucose. Using a high fat diet-fed NAFLD model
where bromodichloromethane (BDCM) was administered to induce CYP2E1-mediated
oxidative stress, we show that P2X7r expression and protein levels were leptin and
CYP2E1 dependent. P2X7r KO mice had significantly decreased stellate cell proliferation.
Human NASH livers showed marked increase in P2X7r, and Glut4 in α-SMA positive
7

cells. NASH livers had significant increase in Glut4 protein and phosphorylated AKT,
needed for Glut4 translocation while leptin KO and P2X7r KO mice showed marked
decrease in Glut4 levels primarily in stellate cells. Mechanistically stellate cells showed
increase in phosphorylated AKT, Glut4 protein and localization in the membrane following
administration of P2X7r agonist or leptin+P2X7r agonist, while use of P2X7r antagonist
or AKT inhibitor attenuated the response suggesting that leptin-P2X7r axis in concert but
not leptin alone is responsible for the Glut4 induction and translocation. Finally P2X7ragonist and leptin caused increase in intracellular glucose and consumption by increasing
the activity of hexokinase. In conclusion, the study shows a novel role of leptin-induced
P2X7r in modulating Glut4 induction and translocation in hepatic stellate cells, that are
key to NASH progression.
2.1 INTRODUCTION
There has been a recent emphasis on the role of CYP2E1 in the development of
nonalcoholic steatohepatitis, a progressive liver disease arising from a pronounced obese
phenotype and a fatty liver (18, 37-40). CYP2E1 has been found to generate metabolic
oxidative stress, a known “second hit” for the progression of NASH from benign steatosis
(41). Interestingly, steatosis has been shown to be protective but a series of concomitant
conditions like formation of free radicals, oxidative stress driven cytokine increase drives
a inflammatory phenotype in the fatty liver (30, 42-44). NASH is characterized by severe
metabolic disturbances that include hepatic insulin resistance, higher leptin, glucose
intolerance and disturbances in lipid metabolism (45-47). NASH also is often associated
with fibrotic phenotype due to increased proliferation and altered morphology of stellate
cells (48, 49). Stellate cells that are residents of the “space of Disse” are specialized cells
8

for fat storage and lose their stored lipids to obtain a fibroblastic lineage during the
progression of NASH (50).
Hepatic insulin resistance is a common occurrence in NASH and insulin signaling
is defective in most cell types in the liver (51, 52). Though liver insulin resistance is
common, stellate cells have been shown to utilize glucose rapidly during their proliferative
phase (53, 54). The lack of insulin signaling or mechanisms of selective insulin response
in the stellate cells has been unclear. Though selective insulin signaling has been shown to
be preserved in adipocytes by the way of differential responses of GLUT4 translocation
and lipogenesis via nuclear expulsion of FoxO1, alternative routes of mediators of GLUT4
translocation has been unknown (55). Insulin effects on GLUT4 translocation has been
primarily found to be AKT phosphorylation mediated while defects of the insulin signaling
process has been found to completely abrogate glucose utilization in the adipocytes (55).
There is a significant knowledge gap in understanding alternative signaling mediators in
mediating GLUT4 translocation, induction and increased intracellular glucose transport
especially in NASH.
Leptin resistance is common in human NASH (56). We and others have shown that
CYP2E1-derived oxidative stress increases leptin levels in the liver, induces NADPH
oxidase derived protein free radicals (57, 58). Leptin also has been shown to be a key driver
of stellate cell activation, proliferation and fibrosis in NASH (59, 60). Leptin is also
responsible in GLUT4 translocation and glucose uptake in stellate cells and cells of
neuronal origin though the exact pathways and molecular mediators of its function are
largely elusive (54, 61). Our recent laboratory observations coupled with several other
reports of the role of purinergic receptors, in causing Kupffer cell activation, autophagy
9

and NASH progression have thrown important light on the role of these innate immune
mediators in NASH (23, 31, 62, 63). P2X7 receptors are ion channels responsive to high
concentrations of ATP that is released following cellular necrosis (23, 64). P2X7 receptors
upon activation are known to perform several important cellular tasks including caspase-1
dependent IL1β production and in lipid metabolism (23, 65). The P2X7 receptor (P2X7r)
is one such multifunctional protein that is related to multiple partners and signaling
pathways (66). The P2X7r-lipid metabolism pathway is related to many biological
functions of P2X7R, such as cell death and pathogen clearance (67). This signaling
pathway may be involved in many functions that are dependent on bioactive lipids,
activation of the different cellular signaling pathways that may mimic insulin signaling and
provide an explanation to the differential behavior of stellate cell glucose transport and
proliferative responses even in a state of profound insulin resistance (68).
In this study we hypothesize that CYP2E1 driven oxidative stress and increased
leptin results in P2X7r induction and concomitant activation leading to AKT pathway
activation. The increased phosphorylation of AKT leads to GLUT4 translocation to the
stellate cell membranes resulting in increased intracellular glucose and stellate cell
activation in NASH. We use a diet induced obese mouse model to have a fatty liver
phenotype (Simple steatosis) with no inflammation or fibrosis (NAFLD group) (69).
CYP2E1 mediated oxidative stress is generated by administering a hepatotoxin
bromodichloromethane (BDCM). We chose to use the steatosis stage of NAFLD with no
inflammation or fibrosis to demonstrate the effect of metabolic oxidative stress and its
consequences.

10

Our results from both in-vivo (mouse model of NAFLD) and in-vitro models (rat
stellate cells) show that increased leptin due to CYP2E1 derived oxidative stress induce
P2X7r and activates it resulting in increased GLUT4 protein levels in stellate cells. The
GLUT4 translocation is also increased in these cells following co-incubation with P2X7r
agonist and is mediated by AKT phosphorylation. The above mechanisms suggested that
leptin induced P2X7r activation might be key to the glucose utilization and high energy
demand for proliferating stellate cells.
2.2 MATERIALS AND METHODS
Mice model for NAFLD: Pathogen-free, adult, male mice with C57BL/6J background
(Jackson Laboratories, Bar Harbor, ME) were used in the study. They were fed with a highfat diet (60% kcal fat) from 6 wk to 16 wk and used as a model of nonalcoholic fatty liver
disease (NAFLD). All experiments were conducted at the completion of 16 wk. The
animals were housed one in each cage before any experimental use. Mice that contained
the deleted purinergic receptor X7 gene (P2X7r KO) (B6.129P2-P2rx7tm1Gab/J) and mice
that contained the disrupted OB gene (leptin) (B6.V-Lep<ob>/J) (Lep KO) were purchased
from Jackson Laboratories. All groups of mice were fed with a high-fat diet and treated
identically to NAFLD mice. All groups of mice had ad libitum access to food and water
and were housed in a temperature-controlled room at 23–24°C with a 12-h:12-h light/dark
cycle. All animals were treated in strict accordance with the NIH Guide for the Humane
Care and Use of Laboratory Animals, and the experiments were approved by the
institutional review boards at NIEHS, Duke University, and the University of South
Carolina at Columbia. The high fat diet was procured from Research Diet Inc, USA
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Induction of liver injury in obese mice (Toxin Model): NAFLD mice or high-fat diet
fed gene specific knockout mice (P2X7r KO and Lep KO) were administered with
bromodichloromethane (BDCM) (1.0 mmol/kg, diluted in olive oil) through the
intraperitoneal route twice a week for 4 weeks to assess the effects of chronic exposure of
BDCM (NAFLD+BDCM, P2X7r KO and Lep KO). However, NAFLD mice treated with
olive oil (diluent of BDCM) were used as control (NAFLD). After completion of the
treatment, mice of all study groups were sacrificed for liver tissue and serum for the further
experiments.
Inhibition of CYP2E1 by diallyl sulfide: A set of high-fat diet fed, BDCM treated mice
(NAFLD+BDCM) were administered with 50mg/kg diallyl sulfide (diluted in corn oil) via
intraperitoneal injection, twice a week for 4 weeks. This group of mice was referred as
DAS.
Immunohistochemistry: Formalin-fixed, paraffin-embedded liver tissue from all the mice
groups were cut into 5 μm thick tissue sections. Each section was deparaffinized using
standard protocol. Briefly, sections were incubated with xylene twice for 3 min, washed
with xylene:ethanol (1:1) for 3 min, and rehydrated through a series of ethanol (twice with
100%, 95%, 70%, 50%), twice with distilled water, and finally rinsed twice with PBS
(Sigma-Aldrich). Epitope retrieval of deparaffinized sections was carried out using epitope
retrieval solution and steamer (IHC-World, Woodstock, - MD) following the
manufacturer's protocol. The primary antibodies anti-P2X7r, anti-α- SMA and anti-GLUT4
were purchased from Abcam (Cambridge, MA) and used in 1:250 dilutions. Antigenspecific immunohistochemistry were performed using Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine
12

(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by
Mayer's hematoxylin (Sigma-Aldrich). A double stain IHC was performed for dual labeling
of GLUT4 and α SMA using the MULTIVIEW® (mouse-HRP/mouse-AP) IHC kit from
Enzo life Sciences (Farmingdale, NY). The sections were deparaffinized as described
above and staining was performed according to manufacturer’s instructions. Washing with
PBS (Sigma-Aldrich) was performed thrice between the steps. Sections were mounted in
simpo mount (GBI Laboratories, Mukilteo, WA) and observed under a 20X oil objective.
Morphometric analysis was done using CellSens Software from Olympus America.
Quantitative RT-PCR: Gene expression levels in tissue samples were measured by twostep qRT-PCR. Total RNA was isolated from liver tissue and cells grown in a monolayer
by homogenization in TRIzol reagent (Invitrogen) according to the manufacturer's
instructions and purified with the use of RNeasy mini kit columns (Qiagen, Valencia, CA).
Purified RNA (1 μg) was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad)
following the manufacturer's standard protocol. qRT-PCR was performed with the genespecific primers using SsoAdvanced SYBR Green supermix (Bio-Rad) and CFX96 thermal
cycler (Bio-Rad). Threshold Cycle (Ct) values for the selected genes were normalized
against 18S (internal control) values in the same sample. Each reaction was carried out in
triplicate for each gene and for each tissue sample. NAFLD mouse liver sample was used
as the control for comparison with all other liver samples form study groups of mice. The
relative fold change was calculated by the 2−ΔΔCt method. The sequences for the primers
used for real-time PCR are provided in Table1.
Immuno Blotting: Tissue (30 mg) from each liver sample was homogenized in 500 μl of
RIPA buffer (Sigma-Aldrich) with protease inhibitor (1X) (Pierce, Rockford, IL) using
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dounce homogenizer. For cells growing in monolayer were harvested using 0.05% TrypsinEDTA (Gibco) and lysed in MPER lysis buffer (100µL) (Thermo-Scientific). The lysate
was sonicated using the branson ultrasound sonicator. The homogenate was centrifuged
and supernatant used for SDS PAGE western blotting. 30 µg of protein from each sample
was loaded on Novex (Invitrogen, Carlsbad, CA) 4–12% bis-tris gradient gel and run for
completion of SDS PAGE. Resolved proteins bands were transferred to nitrocellulose
membrane using precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories,
Hercules, CA) and Trans-Blot Turbo transfer system (Bio-Rad) in case of low molecular
weight proteins and using wet transfer module from Invitrogen in case of high molecular
weight proteins. A solution of 5% non-fat milk was used for blocking. Primary antibodies
against α-SMA, GLUT4, p-AKT and β-actin, Total AKT (all were purchased from
Abcam), at recommended dilutions, and compatible horseradish peroxidase-conjugated
secondary antibodies were used. Pierce ECL Western Blotting substrate (Thermo Fisher
Scientific, Rockford, IL) was used. The blot was imaged using G:Box Chemi XX6
(Syngene imaging systems) and subjected to densitometry analysis using Image J.
Cell culture and treatments: Immortalised rat hepatic stellate cell line (8B) kindly
provided to us by Dr. Anna Mae Diehl (Duke-Gastroenterology), were maintained in high
glucose Dulbelccos modified eagles medium (DMEM), Corning (Tewksbury, MA)
supplemented with 10% fetal bovine serum (FBS), Atlanta biologicals (Norcross, GA)
suplimented with 2mM glutamine, 100U/ml Penicillin, and 100μg/ml streptomycin; Gibco
(Grand Island, NY) at 37oC in a humidified atmosphere of 5% CO2. The cells were then
treated with Leptin 100ng/ml, Biovision (Milpitas, CA) (Lep), Benzoyl ATP as P2X7r
Agonist (P7 Ag), 50µM P13K inhibitor (LY294002) (AKTi) and 100µM P2X7r
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Antagonist (A438079) (P7 An), separately or in combination with Leptin and Benzoyl ATP
(Lep+P7 Ag), Leptin and A438079 (Lep+P7 An), Leptin and LY294002 (Lep+AKTi),
Leptin and Benzoyl ATP and LY294002 (Lep+P7 Ag+AKTi) for 48 h and processed for
future experiments. The inhibitors and agonist were purchased from SantaCruz
Biotechnology (Dallas, TX). Freshly isolated rat hepatocytes (TRL, Research triangle park,
NC) were incubated with high glucose DMEM media supplemented with 10% FBS and
exposed to 100μM BDCM for 48 h at 37oC in a humidified atmosphere of 5% CO2. The
cells were harvested and supernatant were used as a conditioned media for hepatic stellate
cells. 8B cells were incubated with 1:5 fold diluted conditioned media (CM) alone or in
combination with LY294002 (CM+AKTi) for 48 h and cells were used for further
experiments.
Immuno-fluorescence: Treated and control 8B cells were fixed in 10% Neutral buffered
Formalin for 15 min at room temperature (RT). They were then permeablized in PBS with
0.1% Triton X (PBSTx) for 10 min followed by blocking with PBS containing 10% fetal
bovine serum, 3% bovine serum albumin and 0.2% Tween 20 for 1h, then incubated with
primary antibodies GLUT4 and p-AKT (1:1000) diluted in blocking buffer at 4˚C
overnight. Cells were washed thrice in PBSTx for 10 min each. The cells were then
incubated with compatible AlexaFlour conjugated secondary antibodies 633 (red) for
GLUT4 and 488 (green) for p-AKT from Invitrogen. (Grand Island, NY), followed by three
washes in PBSTx for 10 min each. Finally, the cells were mounted in Prolong gold antifade
reagent with DAPI. Images were taken under 40X objective using the Olympus BX51
microscope.
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Biochemical assays for intracellular glucose and hexokinase activity: Intracellular
glucose concentration was measured using the Amplex Red Glucose/Glucose Oxidase
assay kit (Invitrogen) and intracellular hexokinase activity was measured using Hexokinase
colorimetric assay kit Biovision (Milpitas, CA). All procedures were followed according
to manufacturer’s instructions. The resulting glucose and hexokinase values were
normalized to the total protein concentration of the samples measured by Bradford’s
reagent.
Statistical Analyses: All experiments were repeated three times with 3 mice per group (N
= 3; data from each group of mice was pooled). The statistical analysis was carried out by
analysis of variance (ANOVA) followed by the Bonferroni posthoc correction for
intergroup comparisons. Quantitative data from western blots as depicted by the relative
intensity of the bands were analyzed by performing a student’s t test. P<0.05 was
considered statistically significant.
2.3 RESULTS
P2X7r protein expression in the NAFLD liver is modulated by CYP2E1-mediated
oxidative stress and adipokine leptin.

We have shown previously that CYP2E1-

mediated oxidative stress increases hepatic leptin and P2X7r both at mRNA and protein
levels (57, 62). This observation was also elucidated by Ikejima K et al where CCl4,
CYP2E1 substrate, administration increased leptin levels (58). Since leptin is shown
previously to be aiding in stellate cell proliferation and fibrogenesis, we wanted to study
novel downstream mechanisms of leptin action and its crosstalk with P2X7r in the liver
(70, 71). Results showed that the immunoreactivity of P2X7r in the NAFLD liver that was
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co-administered with the hepatoxin BDCM, a substrate of CYP2E1 showed a significant
increase as compared to NAFLD mice alone (Figure. 2.1 A and 2.1 B) (P<0.05). Mice
treated with CYP2E1 inhibitor diallyl sulfide (DAS) or mice that were deficient in leptin
(Lep

KO)

showed

a

significant

decrease

in

the

P2X7r

immunoreactivity

(immunohistochemistry on liver slices) when compared to NAFLD+BDCM group (Fig.
2.1 A and 2.1 B) (P<0.05). There was a significant increase in the mRNA expression of
P2X7r in NAFLD+BDCM group as compared to NAFLD group alone while
administration of DAS or use of Leptin KO mice significantly decreased P2X7r mRNA
expression suggesting that the P2X7r protein might be intrinsic to the diseased liver
(Figure. 2.1 C) (P<0.05). NAFLD group had significant micro and macro vesicular
steatosis while NAFLD+BDCM group had higher macrovesicular fibrosis when compared
to NAFLD group alone as shown by Oil Red-O stain (Figure 2.1 D). Interestingly P2X7r
KO mice showed marked decrease in Oil Red O stain when compared to NAFLD groups.
Leptin-induced P2X7r is required for stellate cell activation in progressive liver
injury of NAFLD mice. Leptin has been shown to aid in the proliferation of stellate cells
(59, 72-74). The stellate cells are crucial for the wound healing response in the liver though
it has been shown to be involved in fibrotic pathology of progressive NAFLD and
development of hepatocellular carcinoma (75). On the other hand P2X7 receptor activation
has been shown to participate in NASH pathophysiology via the inflammosome formation
but detailed mechanisms are unclear (23, 63). To study the role of leptin induced P2X7r
activation in stellate cell proliferation in progressive NAFLD following CYP2E1 mediated
oxidative stress, immunohistochemistry, western blot analysis and mRNA expression of
stellate cell activation marker α-SMA were studied. Results showed that there was a
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significant increase in sinusoidal immunoreactivity of α- SMA in NAFLD+BDCM group
as compared to NAFLD group alone (Figure. 2.2 A and 2.2 B) (P<0.05). Use of leptin and
P2X7r KO mice significantly decreased the immunoreactivity of α-SMA in the liver slices
(Figure. 2.2 A and 2.2 B). NAFLD+BDCM group had a significant increase (>6fold) in αSMA mRNA expression as compared to NAFLD group alone while lack of leptin or P2X7r
had significantly decreased expression of the α-SMA mRNA (Figure. 2.2 C) (P<0.05).
Western blot analysis of α-SMA protein in liver homogenates showed a significant increase
of the protein in NAFLD+BDCM group as compared to NAFLD group alone while use of
liver homogenates from Leptin or P2X7r KO mice showed a significant decrease in the
band reactivity when measured by Image J software (Figure. 2.2 D and 2.2 E) (P<0.05).
Leptin-induced P2X7r modulates GLUT4 levels in murine NASH livers. Leptin has
been extensively studied for its role in the energy homeostasis and metabolism (76).
However, due to the higher levels of leptin in obese subjects as well as in fatty liver disease,
it is unclear when and where leptin function is regulated especially in the liver (77). Stellate
cells acquire a proliferating phenotype in liver injury and require increased glucose
transport into the cells apart from rapid utilization of glucose to meet its energy needs (54,
78). To show whether leptin induced P2X7r modulates GLUT4, a principal glucose
transporter in the liver, mRNA expressions, protein levels and localization of GLUT4 were
studied. Results showed that GLUT4 mRNA expression was significantly upregulated
(>70 fold) in the liver of NAFLD+BDCM group as compared to NAFLD alone (Figure.
2.3 A) (P<0.05) whereas use of P2X7r or Leptin KO mice livers had significantly decreased
mRNA expressions of GLUT4 (Figure. 2.3 A)(P<0.05). Protein levels of GLUT4 as shown
by western blot showed a significant increase in NAFLD+BDCM group as compared to
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NAFLD group alone (Figure. 2.3 B and 2.3 C) (P<0.05). Use of leptin KO or P2X7r KO
mice treated with BDCM showed a significant decrease in the protein levels of GLUT4 in
the liver (Figure 2.3 B-2.3 E) (P<0.05). Since western analysis of GLUT4 protein in the
liver could not help in the identity of a particular cell type where the GLUT4 expression
might be the highest, we performed immunohistochemistry. Results showed that GLUT4
induction was highest in the sinusoidal cells in the NAFLD+BDCM group as compared to
NAFLD group alone (Figure. 2.3 F and 2.3 G) (P<0.05) while leptin KO or P2X7r KO had
a significant decrease in the GLUT4 staining in these cell types. Since activated stellate
cells have been shown to utilize higher glucose primarily through GLUT4, we studied the
GLUT4 localization in activated stellate cells (54). Dual labelling immunohistochemistry
(Red: GLUT4, Brown: α-SMA), showed a markedly higher number of co-localizations of
GLUT4 protein and stellate cell activation marker α-SMA (Figure. 2.3 H) suggesting that
the activated stellate cells might have an increased expression and levels of GLUT4
following oxidative stress injury in progressive NAFLD model. Similar Glut4-α-SMA colocalizations were also observed in human NASH samples when compared with human
controls suggesting a strong correlation with the studies in mouse model of NASH (Figure
2.3 I). Glut4 protein levels also showed a significant increase in rat hepatic stellate cells
when stimulated with a P2X7r agonist and leptin (Figure 2.3 J) followed by a similar
increase in P2X7r protein in these cells (Figure 2.3 K).
Lack of Leptin or P2X7r decreases phosphorylation of AKT in oxidative stress
induced liver injury in progressive NAFLD mice. The downstream pathways of Leptin
and P2X7r activation have been shown to act through PI3/AKT pathway with subsequent
phosphorylation of AKT (61, 66). Based on our previous results in this study, it was
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important that we study AKT phosphorylation as a result of leptin induction of P2X7r and
subsequent activation of the purinergic receptor isoform. Results showed that
NAFLD+BDCM group had significantly higher levels of p-AKT protein as compared to
NAFLD group alone (Figure 2.4 A-2.4 D) (P<0.05). Use of leptin KO mice or mice that
were devoid of P2X7r showed significant decrease in the P-AKT protein levels as
measured by western blot analysis (Figure 2.4 A-2.4 D) (P<0.05). The results suggested
that the injured liver of NAFLD mice that had leptin induced P2X7r induction and
subsequent activation might modulate the functions of the diseased liver via the AKT
pathway and correlate well with the downstream events of these molecules. However, the
suggested data is premature at this point since mere estimation of pAKT levels in the liver
does not explain the relationship of leptin-induced P2X7 activation and the corresponding
signaling events. To show conclusively that leptin-induced P2X7r signaling is mediated
through AKT phosphorylation in activated stellate cells, rat myofibroblast 8B cells were
used. Results showed that co-incubation of cells with leptin (100ng/ml) significantly
increased AKT phosphorylation as compared to medium only group (Figure. 2.4 E.i and
2.4 E.iii). Cells treated with P2X7r agonist Bz-ATP (P7 Ag) also increased AKT
phosphorylation

significantly

when

compared

to

controls

as

shown

by

immunofluorescence microscopy and morphometry (Figure. 2.4 E.i and 2.4 E .ii) (2.4 F)
(P<0.05). The increase in AKT phosphorylation was significantly higher than the leptin
treated cells (Figure. 2.4 E.iii) (2.4 F) (P<0.05). Use of AKT inhibitor significantly
decreased the fluorescent intensity (Figure. 2.4 E v and vi), (The decrease was more
pronounced in the Leptin+P2X7r agonist group than leptin or P2X7r agonist treated alone)
in cells treated with both leptin and P2X7r agonist suggesting that P2X7r-mediated AKT

20

phosphorylation is downstream of leptin. Use of P2X7r antagonist significantly decreased
the AKT phosphorylation induced by leptin (vii) (Figure. 2.4 F). Use of conditioned
medium increased AKT phosphorylation (Figure. 2.4 E viii and ix) while AKT inhibitor
significantly decreased it. The above results suggested that P2X7r mediated
phosphorylation of AKT was (a) downstream of leptin and (b) was the principal driver of
AKT phosphorylation since use of the agonist attenuated the phosphorylation completely.
However, leptin-induced AKT phosphorylation is not ruled out in these cells and it is
unclear at this point whether there is any parallel role leptin-induced AKT phosphorylation.
P2X7r activation and subsequent AKT pathway modulates GLUT4 induction and
translocation in stellate cells. To study the role of P2X7r-mediated signaling and the AKT
pathway in GLUT4 induction and translocation to the membrane, a transformed rat stellate
cell line was used. GLUT4 translocation has been shown to be a major event in glucose
transport across the membrane and is key to increased stellate cell proliferation (54). Cells
incubated with leptin were later fixed and immunoreactivity to GLUT4 was analyzed by
immunofluorescence microscopy. Results showed that cells treated with leptin (Figure. 2.5
v) or P2X7 agonist (Figure. 2.5 ii) had a significant increase in both the cytoplasmic and
membrane localizations of GLUT4 as compared to untreated control (Figure 2.5 i) cells.
Interestingly, cells that were incubated with both leptin and P2X7r agonist had a marked
increase in both localization of GLUT4 in the cell membrane as well as strong protein
levels in the cytoplasm as compared to either leptin alone or P2X7r agonist treated cells.
The data suggested a strong synergistic effect on GLUT4 (Figure. 2.5 vi) localization and
protein induction. Treatment of leptin-primed cells with P2X7r antagonist completely
abrogated the GLUT4 induction and translocation (Figure. 2.5 iv and 2.5 vi). A parallel use
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of AKT inhibitor with P2X7 agonist treated cells or with conditioned medium markedly
decreased Glut4 protein and localization suggesting P2X7r and AKT phosphorylation
mediated GLUT4 translocation and induction were downstream of leptin (Figure. 2.5 iv
and 2.5 ix). To prove that the cellular microenvironment in diseased liver cross talks with
each other in the form of paracrine fashion and influences stellate cell GLUT4 induction
and translocation, cells were incubated with a conditioned medium that was generated by
treating hepatocytes with BDCM. Results showed that cells treated with conditioned
medium had marked increase in GLUT4 protein and its localization in the membrane as
compared to medium controls (Figure. 2.5 viii) whereas, co-incubation with AKT inhibitor
markedly decreased the fluorescent intensity (Figure. 2.5 ix), suggesting that hepatocytestellate cell crosstalk might be a significant event that influences P2X7r mediation of
GLUT4 induction and translocation to the membrane.
P2X7r activation leads to increased intracellular glucose and hexokinase acivity in
stellate cells. The fate of hepatic stellate cells in liver injury involves a crucial regulation
of metabolism in these cells (79, 80). The trans-differentiation of stellate cells from a
quiescent state to a highly proliferative state requires rapid glucose uptake and possibly a
higher utilization of the glucose stores for enhanced glycolysis (79). To show that P2X7r
mediated GLUT4 induction and translocation regulated intracellular glucose levels by
increasing glucose uptake, concentrations of stellate cell glucose were estimated through a
biochemical assay. Results showed that P2X7 agonist and leptin significantly raised
intracellular glucose levels as compared untreated cells (Figure. 2.6 A) (P<0.05).
Administration of P2X7r antagonist significantly decreased the intracellular glucose levels
(Figure. 2.6 A) (P<0.05). Since hexokinase levels remain high and its activity is key to
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glucose utilization in stellate cells for glycolytic pathway, as evidenced in situations where
the stellate cell acquires a myofibroblastic lineage, we studied the fate of the increased
intracellular glucose by measuring the activity of hexokinase (HK) (54). Results showed
that co-incubation of cells with P2X7 agonist or leptin significantly upregulated the activity
of HK by 45-50% (Fig. 2.6 B) (P<0.05), whereas administration of the P2X7r antagonist
significantly decreased the HK activity (Figure. 2.6 B) (P<0.05). The results suggested that
leptin and p2X7 r modulated glucose metabolic fate in stellate cells possibly by its actions
on GLUT4 induction and translocation and the two events were closely correlated.
2.4 DISCUSSION
The present study shows a novel role of P2X7r in modulating GLUT4 induction and
translocation in hepatic stellate cells. The study which uses an experimental murine model
of NAFLD with concomitant metabolic oxidative stress as a “second hit” outlines a
mechanistic investigation of the role of leptin, P2X7r induction, GLUT4 translocation and
finally higher intracellular glucose in hepatic stellate cells. The study is significant since it
identifies a new mediator for stellate cell activation and proliferation crucial for NASH
progression.
We and others have shown previously that metabolic oxidative stress increases
systemic and hepatic leptin levels over and above the levels found in obesity (57, 58).
Increased leptin can perform an array of functions or dysfunctions that affect a myriad of
pathways causing dysregulation in immune, endothelial and metabolic functions in NASH
(71). Leptin has been shown to cause increased GLUT4 translocation in stellate cells apart
from its more established role of causing increased stellate cell proliferation but the
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downstream mechanisms in metabolic alterations in these cells have been unclear (54).
Since there are several literature reports including reports from our laboratory that suggest
the strong involvement of P2X7r in inflammatory and cell fate regulations in the
hepatocellular microenvironment, we argued that circulating leptin might induce P2X7r
and leptin-mediated P2X7r activation in NASH might have a role in the metabolic
dysregulation in the liver especially in stellate cells (62, 63). Interestingly Dranoff JA. Et
al reported a strong involvement of P2Y receptor subtypes in activated stellate cells (81).
The present study did not explore the role of the P2Y receptors in NASH development due
to our earlier observations that P2X7r was crucial for NADPH oxidase induced reactive
oxygen species generation, autophagy and altered pathogenesis in NASH. We are not
aware of any studies that link P2Y receptors with NADPH oxidase activation in vivo.
However, it is possible that significant crosstalk may exist among different P2 receptors
owing to their activation by nucleosides. Our data of attenuated P2X7r protein levels in
leptin knockout mice show the strong role of leptin in inducing these receptors in the NASH
liver (Figure. 2.1 B and 2.1 C; >7 fold decrease in protein). However, caution needs to be
exerted in interpretation of this particular data since the current study does not show by
way of leptin supplementation in leptin KO mice, whether there is a strong upregulation of
P2X7r in these livers. Our data of decreased P2X7r in DAS treated livers also correlates
well with the argument that oxidative stress, increased leptin and P2X7r induction and/or
activation might be strongly associated (Fig. 2.1).
We have shown previously that P2X7r KO mice are protected from NASH
associated fibrosis (62). In this study P2X7r knockout mice also had significantly decreased
stellate cell activation as was indicated by decreased immunoreactivity of α-SMA in NASH
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livers (Figure. 2.2). Stellate cell transdifferentiation from a quiescent stage to a more
myofibroblastic lineage followed by proliferation is a significant event in NASH (79, 82).
Studies have shown that the altered phenotype of stellate cells due to liver injury causes a
significant alteration of its metabolic machinery which includes increased glucose
utilization and a preferable use of the glycolytic machinery even in aerobic circumstances
(79). The above metabolic pattern requires GLUT4 translocation to the membrane for
transporting increased glucose into the cell (54). Leptin has been shown to be involved in
the process of translocation of GLUT4 to the membrane but we are not aware of any studies
that also reported its induction by leptin or its downstream mediators (54). Our study shows
that leptin-induced P2X7r was required for induction of GLUT4 in the liver as shown by
qRTPCR, western blot and IHC analysis since both leptin KO mice and P2X7r KO mice
had decreased GLUT4 with P2X7r KO showing a more pronounced depletion of the
GLUT4 immunoreactive band (Fig. 2.3 E). Interestingly P2X7r KO mice barely expressed
GLUT4 mRNA suggesting a strong transcriptional regulation of the GLUT4 protein by
P2X7r in the injured liver (Fig. 2.3 A). GLUT2 and GLUT4 are cellular glucose
transporters found in the liver probably in every cell type (83, 84). Some studies suggest
that insulin and insulin-like growth factor-1 are mitogenic for Hepatic Stellate Cells
(HSC’s) in spite of the fact that insulin resistance is a common etiology in NASH (85-88).
GLUT4 has been shown to be insulin responsive in hepatocytes and stellate cells and is
tightly regulated primarily by activated PI3K (54, 83). As a response from insulin
signaling, GLUT4 is rapidly translocated to the cell membrane to allow more glucose
influx (61, 89). The high glucose then stimulates increased consumption in cells
undergoing proliferation or that are in need for higher metabolic activity (90). Stellate cells,
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due to their higher metabolic activity in injured liver are unique since NASH has
documented insulin and leptin resistance (47). It is unclear how the stellate cells still
respond to insulin and leptin. To prove that activated stellate cells and not any other cell
types express higher GLUT4 in NASH liver, we conducted immunohistochemistry of
GLUT4 (Figure. 2.3 F). Firstly, we found higher GLUT4 in sinusoidal cells and secondly,
we observed co-localization of GLUT4 and α-SMA in the liver slices (Figure 2.3 H). The
same results were obtained with human liver slices where NASH livers showed a marked
increase in P2X7r (Figure 2.3 I). Importantly, Lep KO or P2X7r KO mice had significantly
lower GLUT4 in stellate cells (Figure. 2.3 F). Based on these observations we argued that
owing to the importance of stellate cells in an injured liver, primarily for wound healing
response, there may be parallel (Insulin based-already known) and/or leptin-linked P2X7rmediated signaling pathway that help in maintaining their high metabolic activity in
NASH. The higher metabolic activity may initiate more glucose influx into these cells
primarily by increased GLUT4 induction and translocation. Firstly, to strengthen our
argument for an overt role of AKT pathway downstream of leptin-P2X7r axis we
performed in vitro experiments in rat stellate cells. Our data of attenuation of AKT
phosphorylation by the co-incubation with P2X7r antagonist in cells stimulated with leptin
showed that P2X7r was central to leptin-induced AKT phosphorylation (Figure. 2.4 E and
F). Further confirmation of the role of P2X7r induced GLUT4 induction and translocation
in stellate cells were achieved following in vitro experiments in stellate cells and
immunofluorescence microscopy. Results showed that P2X7r agonist +Leptin had a
marked increase in both protein levels and membrane localization of GLUT4 while use of
P2X7r antagonist abrogated it (Figure. 2.5 vii). Incubation with a hepatocyte derived
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conditioned medium also significantly increased induction and translocation of GLUT4,
while use of AKT inhibitor attenuated both of these functions. It is worth mentioning that
P2X7r has been shown to be activated by ATP released from necrosed hepatocytes
following CYP2E1 mediated oxidative stress (30). The conditioned medium used in this
study was also generated in the same method where BDCM was used to be a substrate of
CYP2E1 in place of CCl4. It is justifiable to assume that the conditioned medium is a good
example of cellular microenvironment in NASH where necrosed hepatocytes can activate
P2X7r on stellate cells and cause their metabolic alterations, increased responsiveness to
higher GLUT4 and stellate cell proliferation via AKT pathway. Finally, we also showed
that P2X7r-mediated higher GLUT4 protein and translocation resulted in higher glucose
concentration in the stellate cells and this was followed by increased glucose consumption
only to be attenuated by use of P2X7r antagonist and AKT inhibitor. Studies have shown
that stellate cell proliferation requires higher glucose consumption and increased
hexokinase activity (HK) which creates a gradient that allows more glucose to be brought
into the cell (91). Our results of increased HK activity in the stellate cells primarily by
P2X7r activation is a strong indication of leptin-P2X7r axis in modulating stellate cell
response in NASH though we have no direct evidence to prove this mechanism in vivo.
Finally, our results suggested that though insulin resistance is rampant in NASH, stellate
cells are responsive to leptin-induced P2X7r-mediated glucose influx primarily through
induction and translocation of GLUT4. Mechanistically, the induction and translocation
might be mediated by AKT phosphorylation initiated by P2X7r (Figure. 2.7). However,
doubts still remain whether the AKT phosphorylation induced by insulin signaling acts in
parallel to P2X7r or they act in concert and these two mediators are linked. Another
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limitation in this study is the mechanism of leptin-induced P2X7r expression or activation.
Interestingly our results show that leptin knockout mice have a significant decrease in
P2X7r induction, a sign of a direct influence of leptin signaling on P2X7r induction. It may
be possible that leptin-induced NADPH oxidase activation and subsequent release of
reactive oxygen species may be responsible for P2X7 induction, a hypothesis that needs
further exploration. The hypothesis is strengthened by the fact that invivo experiments
suggested a parallel paracrine signaling influences Glut4 induction, an event that may see
the involvement of oxidative stress or cell death signals like HMGB1 or extracellular ATP.
Future studies may focus on a P2X7r dependent stellate cell circuit that can be
pharmacologically manipulated to potentiate insulin resistance in NAFLD/ NASH patients.
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Figure.2.1 P2X7r protein expression in the NAFLD liver is modulated by CYP2E1mediated oxidative stress and adipokine Leptin. A: P2X7r immunoreactivity as shown by
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a
model of nonalcoholic fatty liver disease (NAFLD), NAFLD mice exposed to
bromodichloromethane (BDCM) referred as NAFLD+BDCM, NAFLD mice co-exposed
with BDCM and Diallyl sulfide, a known CYP2E1 inhibitor (DAS) and the mice deficient
of leptin gene fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken
at 20X magnification. B: Morphometric analysis of P2X7r immunoreactivity (mean data
from three separate microscopic fields were plotted on Y-axis in NAFLD,
NAFLD+BDCM, DAS and Lep KO groups of mice (*P<0.05). C: mRNA expressions of
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P2X7r in liver tissue of NAFLD, NAFLD+BDCM, DAS and Lep KO groups of mice as
assessed by quantitative real time PCR, the expressions were normalized with 18s and
compared to the NAFLD group and represented as fold changes to NAFLD (*p<0.05).

Figure 2.1 D: Oil Redo staining for lipid accumulation in liver slices from mice fed with
high-fat diet (60% kcal fat) as a model of NAFLD, NAFLD mice exposed to BDCM
(NAFLD+BDCM), the mice deficient of P2X7r gene fed with high-fat diet and exposed to
BDCM (P2X7r KO) and mice deficient of leptin gene fed with high-fat diet and exposed
to BDCM (Lep KO). Images were taken at 20X magnification.
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Figure.2.2 Leptin induced P2X7r is required for stellate cell activation in progressive liver
injury in NAFLD mice. A: Smooth muscle actin (α-SMA) immunoreactivity as shown by
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a
model of NAFLD, NAFLD mice exposed to BDCM (NAFLD+BDCM), the mice deficient
of P2X7r gene fed with high-fat diet and exposed to BDCM (P2X7r KO) and mice deficient
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of leptin gene fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken
at 20X magnification. B: Morphometric analysis of α-SMA immunoreactivity (mean data
from three separate microscopic fields were plotted on Y-axis) in NAFLD,
NAFLD+BDCM, P2X7r KO and Lep KO groups of mice (*P<0.05). C: mRNA
expressions of α-SMA in liver tissue of NAFLD, NAFLD+BDCM, P2X7r KO and Lep
KO groups of mice as assessed by quantitative real time PCR, the expressions were
normalized with 18s and compared to the NAFLD group and represented as fold changes
to NAFLD (*p<0.05). D: Western blot analysis of α-SMA protein levels. Lanes 1–
4 represent NAFLD, NAFLD+BDCM, Lep KO and P2X7r KO. E: Band quantification of
the α-SMA immunoblot in NAFLD, NAFLD+BDCM, Lep KO and P2X7r KO groups of
mice, data was normalized against β-actin (*p<0.05).

Figure.2.3 Leptin induced P2X7r modulates GLUT4 levels in murine NASH livers. A:
mRNA expressions of Glucose transporter 4 (GLUT4) in liver tissue of NAFLD,
NAFLD+BDCM, P2X7r KO and Lep KO groups of mice as assessed by quantitative real
time PCR, the expressions were normalized with internal control (18s) and compared to
the NAFLD group and represented as fold changes to NAFLD (*p<0.05). B: Western blot
analysis of GLUT4 protein levels. Lanes 1–3 represent NAFLD, NAFLD+BDCM and Lep
KO respectively. C: Band quantification of the GLUT4 immunoblot in NAFLD,
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NAFLD+BDCM, Lep KO groups of mice, data was normalized against β-actin (*p<0.05).
D: Western blot analysis of GLUT4 protein levels in liver homogenate of NAFLD,
NAFLD+BDCM and P2X7r KO respectively. E: Band quantification of the GLUT4
immunoblot in NAFLD, NAFLD+BDCM, P2X7r KO groups of mice, data was normalized
against β-actin (*p<0.05).

Figure 2.3 F: GLUT4 immunoreactivity as shown by immunohistochemistry in liver slices
from mice fed with high-fat diet (60% kcal fat) as a model of NAFLD, NAFLD mice
exposed to BDCM (NAFLD+BDCM), the mice deficient of P2X7r gene fed with high-fat
diet and exposed to BDCM (P2X7r KO) and mice deficient of leptin gene fed with highfat diet and exposed to BDCM (Lep KO). Images were taken at 20X magnification. G.
Morphometric analysis of GLUT4 immunoreactivity (mean data from three separate
microscopic fields were plotted on Y-axis) in NAFLD, NAFLD+BDCM, P2X7r KO and
Lep KO groups of mice (*P<0.05).
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Figure 2.3 H: (i-iv). Co-localization of GLUT4 (red) and α-SMA (brown) by
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a
model of NAFLD, NAFLD mice exposed to BDCM (NAFLD+BDCM), P2X7r knockout
mice fed with high-fat diet and exposed to BDCM (P2X7r KO) and leptin knockout mice
fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken at 20X
magnification. (v) 60X oil magnification image of NAFLD+BDCM group to represent colocalization events of GLUT4 (red) and α-SMA (brown). The events were marked with
black solid arrow.
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Figure 2.3 I: Co-localization of GLUT4 (red) and α-SMA (brown) by
immunohistochemistry in liver slices from healthy human control (i) and clinical NASH
patient (ii). Images were taken at 20X magnification. 60X oil magnification image of
healthy human group (iii) and clinical NASH patient (iv) to represent co-localization events
of GLUT4 (red) and α-SMA (brown). The events are marked with a black solid arrow.

Figure 2.3 J: (i) Western blot analysis for Glucose transporter 4 (GLUT4) expression in 8B
rat hepatic stellate cells cultured in high glucose DMEM media with 10%FBS (Med ctrl)
and treated with P2X7r Agonist 100 µM (P7 Ag), P2X7r Antagonist100 µM (P7 An), AKT
inhibitor 50 µM, Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r Agonist (Lep+P7
Ag), Leptin+P7 Antagonist (Lep+P7 An) and Leptin+AKT inhibitor (Lep+AKTi). (ii)
Band quantification GLUT4 immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep,
Lep+P7Ag, Lep+P7An and Lep+AKTi groups, data was normalized against β-Actin. (iii)
mRNA expressions of Glucose transporter 4 (GLUT4) in cell lysates of Med Ctrl, P7Ag,
P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups as assessed by
quantitative real time PCR, the expressions were normalized with internal control (18s)
and compared to the Med Ctrl group and represented as fold changes to Med Ctrl.
(*p<0.05). K: i) Western blot analysis for Purinergic receptor X7 (P2X7r) expression in
Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups. (ii)
Band quantification P2X7r immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag,
Lep+P7An and Lep+AKTi groups, data was normalized against β-Actin. (iii) mRNA
expressions of P2X7r in cell lysates of Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag,
Lep+P7An and Lep+AKTi groups as assessed by quantitative real time PCR, the
expressions were normalized with internal control (18s) and compared to the Med Ctrl
group and represented as fold changes to Med Ctrl. (*p<0.05).
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Figure. 2.4. Lack of Leptin or P2X7r decreases phosphorylation of AKT in oxidative stress
induced liver injury in progressive NAFLD mice. A: Western blot analysis of p-AKT
protein levels in liver homogenate of mice fed with high-fat diet (NAFLD), NAFLD mice
exposed to BDCM (NAFLD+BDCM) and leptin knockout mice fed with high-fat diet and
exposed to BDCM (Lep KO) respectively. B: Band quantification p-AKT immunoblot in
NAFLD, NAFLD+BDCM, Lep KO groups of mice, data was normalized against Total
AKT (*p<0.05). C: Western blot analysis of p-AKT protein in liver homogenate of
NAFLD, NAFLD+BDCM and P2X7r Knockout respectively. D: Band quantification pAKT immunoblot in NAFLD, NAFLD+BDCM, P2X7r KO groups of mice, data was
normalized against Total AKT (*p<0.05).
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Figure 2.4 E: (i-ix). Immunofluorescence for p-AKT expression in 8B rat hepatic stellate
cells cultured in high glucose DMEM media with 10%FBS (Med ctrl) and treated with
P2X7r agonist 100 µM (P7 Ag), Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r
agonist (Lep+P7 Ag), Leptin+AKT inhibitor (Lep+AKTi) and Leptin+P2X7r
Agonist+AKT inhibitor (Lep+P7 Ag+AKTi), Leptin+P7 Antagonist (Lep+P7 An),
hepatocyte conditioned media (CM) and hepatocyte conditioned media+AKT inhibitor
(CM+AKTi). Images were taken at 40X magnification.

Figure 2.4 F: Morphometric analysis of p-AKT immunofluorescence (mean data from three
separate microscopic fields were plotted on Y-axis) in Med Ctrl, P7 Ag, Lep, Lep+P7 Ag,
Lep+AKTi, Lep+P7Ag+AKTi, Lep+P7An, CM and CM+AKTi groups. (*P<0.05).
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Figure 2.4 G: Western blot analysis of p-AKT protein levels in 8 B cell lysate of Med Ctrl,
P7Ag, P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups. H. Band
quantification p-AKT immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag,
Lep+P7An and Lep+AKTi groups, data was normalized against Total AKT.

Figure. 2.5: P2X7r activation and subsequent AKT pathway modulates GLUT4 induction
and translocation in stellate cells. A: (i-ix). Immunofluorescence for GLUT4 expression in
8B rat hepatic stellate cultured in high glucose DMEM media with 10%FBS (Med ctrl) and
treated with P2X7r agonist 100 µM (P7 Ag), P2X7r antagonist 100 µM (P7 An), AKT
inhibitor 50 µM (AKTi), Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r agonist
(Lep+P7 Ag), Leptin+ P2X7r antagonist (Lep+P7An), hepatocyte conditioned media (CM)
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and combination of hepatocyte conditioned media and AKT inhibitor (CM+AKTi). The
GLUT4 has been probed with red immunofluorescence and counterstained with DAPI for
nucleuses (blue). Images were taken at 40X magnification. B: Morphometric analysis of
GLUT4 immunofluorescence (mean data from three separate microscopic fields were
plotted on Y-axis) in Med Ctrl, P7 Ag, P7An, AKTi, Lep, Lep+P7 Ag, Lep+P7An, CM
and CM+AKTi groups. (*P<0.05).

Figure. 2.6. P2X7r activation leads to increased intracellular glucose and hexokinase
activity in stellate cells. A: Intracellular glucose levels in 8B hepatic stellate cells cultured
in high glucose DMEM media with 10% FBS (Med ctrl) and treated with P2X7r agonist
100 µM (P7 Ag), P2X7r antagonist 100 µM (P7 An) and Leptin 100 ng/ml, (Lep)
combination of Leptin+P2X7r agonist (Lep+P7 Ag), Leptin+ P2X7r antagonist. B:
Intracellular hexokinase activity in 8B hepatic stellate cells in Med ctrl, P7 Ag, P7 An and
Lep groups. The intracellular glucose levels and hexokinase activity in 8B cell groups were
normalized against their total protein levels respectively.
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Table 2.1: Table showing the primer sequences for the different targerts used in this study.
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Figure 2.7: A pictorial representation of the molecular process in P2X7r-mediated Glut4
function in NASH hepatic stellate cells.
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CHAPTER 3
P2X7R STIMULATED NLRP3 INFLAMMASOME MEDIATES
PYROPTOSIS IN HEPATIC MACROPHAGES LEADS TO HMGB1
RELEASE IN NON-ALCOHOLIC FATTY LIVER DISEASE.2

2

Chandrashekaran V, Alhasson F, Dattaroy D, Seth RK, Nagarkatti M, Nagarkatti P,
Diehl AM, Chatterjee S P2X7R stimulated NLRP3 inflammasome mediates pyroptosis in
hepatic macrophages leads to HMGB1 release in Non-Alcoholic Fatty liver disease. To
be published.
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Abstract:
Although significant research data exist on the activation of hepatic resident macrophages
(Kupffer cells) in the progression of NAFLD, the mechanisms for it remains largely
elusive. The present study looked at the role of P2X7r cation channel in activating
pyroptosis via NLRP3 inflammasome activation leading to release of damage associated
molecular pattern HMGB1 into the extra cellular environment in these cells. This study
used an early steatohepatitic injury model in high-fat-fed mice. Results showed that
NAFLD mice had increased circulatory HMGB1 levels, along with higher levels of IL-1β
compared to lean controls or P2X7r KO mice. Liver sections of the NAFLD mice showed
successful assembly of the NLRP3 inflammasome and Gasdermin D membrane colocalisation. Mechanistically ATP released from necrosed adjacent hepatocytes activated
the P2X7r channels leading to the assembly of the NLRP3 inflammasome which activates
Caspase 1, active Caspase 1 then cleaves Gasdermin D, a regulator of epithelial cell
proliferation. Cleaved Gasdermin D then oligomerizes and forms membrane pores
releasing HMGB1. In summary, this study shows a novel mechanism of P2X7r mediated
DAMP release in hepatic macrophages due to an underlying condition of NAFLD.
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3.1 INTRODUCTION
Nonalcoholic fatty liver disease is the abnormal accumulation of fat in the liver (<5% total
liver weight) independent of consumption of alcohol. About 30% of the adult American
population is suspected to be affected by this disease. NAFLD is associated with
enlargement and rupture of adipocytes releasing adipokines leading to macrophage
recruitment and inflammation (92). Kupffer cells (KC’s) are resident liver macrophages
located in the hepatic sinusoids and play a central role in innate immunity of the liver, they
represent about 80-90% of all tissue macrophages in the body (93).
Several groups including ours have shown that the activation of KC’s is an
important step in initiation and progression of liver injury (94, 95). There is also
considerable evidence showing that chemical depletion of KC’s can prevent the release of
inflammatory cytokines and alleviate liver damage (96). Activated KC’s secrete a variety
of mediators influencing inflammation and fibrosis. Interestingly, the inflammatory
progress of the disease is regulated by secretion of IL-10 by quiescent (M2) macrophages,
leading to apoptosis of activated macrophages (95). Stressed or dying cells release
endogenous molecules termed as Damage associated molecular patterns (DAMP’s) which
play a crucial role in systemic sterile inflammation. DAMP’s are intracellularly sequestered
molecules that remain unrecognized by the immune system under normal physiological
conditions. However, under conditions of cellular stress or tissue injury, these molecules
are actively released by the stressed immune cells. Though innate immunity mediated
protective inflammatory repair process is believed to be beneficial, this repair mechanisms
can cause harm when associated with chronic inflammation. This is often associated with
overproduction of DAMP’s resulting in acute systemic hyperinflammation (97).
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In pathological conditions such as NAFLD, high levels of ATP are passively
released from necrotic cells (23). ATP, thus released can activate P2X7 receptors (P2X7r)
via the pannexin-1 hemichannel on neighboring cells leading to a localized inflammatory
response. P2X7r are members of the family of ionotrophic ATP gated receptors expressed
virtually on all cells of the innate immune system. Unlike other members of the P2X family,
the P2X7r requires higher amounts of ATP for activation. Activated P2X7r promotes
release of pro-inflammatory cytokines such as IL-6, IL-1β. TNF-α (98). P2X7r is also able
to induce inflammation by recruitment of the NLRP3 inflammasome complex. ATP
mediated P2X7r stimulation leads to an efflux of K+ ions triggering the NLRP3
inflammasome pathway (99). The NLRP3 is a cytoplasmic multiprotein complex,
consisting of the cytoplasmic receptor NLRP3, the adaptor protein ASC and the effector
protein pro-caspase 1. Upon activation, the different scaffold proteins are assembled
bringing several pro-caspase sub-units close to each other. These pro-caspase 1 in close
proximity cleave each other to release the mature or active caspase 1 (100-102). Mature
caspase 1 is then able to cleave pro-IL-1β and pro-IL-18 into their biologically active
forms. Interestingly this process is tightly regulated and requires two hits, where the P2X7r
mediated NLRP3 inflammasome is a secondary signal. First the synthesis of pro-IL-1β and
NLRP3 is triggered by transcriptional induction via NFκB activated via ligands for Toll
like receptors (TLRs). Interestingly TLRs have been shown to be involved in the
pathogenesis of NAFLD (103, 104). A study by Farhadi et al. (105) showed that
endotoxemia resulting from gut leakage could be a cause for NASH. Many reports after
have shown the involvement of endotoxin from the gut as a cause for TLR4 activation and
downstream inflammation (106-110).
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High mobility group box 1 (HMGB1) is a DAMP widely studied as a transcription
factor and growth factor, but recently its role as a cytokine mediator of systemic
inflammation has been identified (111). HMGB1 is released by necrotic or damaged innate
immune cells such as the macrophages. Interestingly HMGB1 is not released by the
apoptotic cells (112) indicating a unique role in progressive inflammation. Pyroptosis is a
unique form of cell death dependent on activation of caspase 1, Pyroptosis leads to rapid
membrane rupture leading to release of proinflammatory intracellular contents (113, 114).
In the present study, we used a rodent model of NAFLD fed on high fat diet for
extended periods of time. Redox stress due to lipotoxicity and innate immune mediation
serve as a secondary hit. In the NAFLD model we detected higher levels of circulating
serum HMGB1, in light of the above evidence, we tested the hypothesis that P2X7r
mediated inflammasome activation along with prevalence of endotoxemia is responsible
for release of HMGB1 in hepatic macrophages. Results showed that P2X7r stimulation
significantly increased levels of extracellular HMGB1 and IL-1β which genetic knockout
or chemical inactivation of the same reversed the effects. Mechanistically ATP released
from necrotic hepatocytes could activate P2X7r channels recruiting the NLRP3
inflammasome. NLRP3 inflammasome was then able to cause membrane pores thereby
releasing HMGB1.
3.2 MATERIALS AND METHODS
Cell culture: Rat immortalized kupffer cell line (Applied Biological Materials Inc.,
Canada) was maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM,
Corning, VA) supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals, CO)
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and 1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY), and grown at
37°C in a humidified incubator with 5% CO2. HBSS buffer, Tissue culture plastic wares
were purchased from Corning (Corning, VA). Stock solution of SsnB was prepared in
dimethyl sulfoxide (DMSO). Before treating the cells with LPS (100ng/ml), cells were
serum starved (DMEM with 0.25% FBS) overnight followed by treatment with Benzoyl
ATP as P2X7r Agonist 100 µM (P7 Ag), and 100µM P2X7r Antagonist (A438079) (P7
An) along with 100 µM (P7 Ag). Control was treated with 0.1% DMSO to remove
background noise. All treatments were given for 24 hours in 0.25% FBS containing DMEM
medium
Mouse Model for NAFLD: Pathogen-free, adult, male mice with C57BL/6J background
(Jackson Laboratories, Bar Harbor, ME) were used in the study. They were fed with a highfat diet (60% kcal fat) (Research diets, New Brunswich, NJ) for 18 weeks and used as a
model of nonalcoholic fatty liver disease (NAFLD). Mice kept on a similar diet for 4 weeks
served as a model for early NAFLD (DIO) where mild steatosis was evident with no liver
inflammation, normal chow diet was used as a model of lean controls. Mice that contained
deleted purinergic receptor X7 gene (P2X7r KO) (B6.129P2-P2rx7tm1Gab/J) were treated
like the NAFLD group (supplementary methods). All groups of mice had ad libitum access
to food and water. All animals were treated in strict accordance with the NIH Guide for the
Humane Care and Use of Laboratory Animals, and the experiments were approved by the
institutional review board at the University of South Carolina at Columbia.
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Laboratory analysis
Immunohistochemistry: Formalin-fixed, paraffin-embedded intestinal and liver tissue
from all the mice groups were cut into 5 μm thick tissue sections. Each section was
deparaffinized (as described in chapter 2). Epitope retrieval of deparaffinized sections was
carried out using epitope retrieval solution and steamer (IHC-World, Woodstock, - MD)
following the manufacturer's protocol. The primary antibodies MCP-1, CD-68, IL-1β,
P2X7r, HMGB1 (Abcam, MA) were used at 1:250 dilutions. Antigen-specific
immunohistochemistry was performed using Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine
(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by
Mayer's hematoxylin (Sigma-Aldrich).
Haematoxylin and Eosin staining: Formalin-fixed tissues were paraffin embedded liver
tissue sections were stained with Haematoxylin and Eosin by the IRF, University of South
Carolina, and School of Medicine.
Immunofluorescence
In vivo: Formalin-fixed, paraffin embedded tissues sections were subjected to
deparaffinization using standard instructions. Epitope retrieval of the deparaffinized
sections was done using epitope retrieval solution and steamer (IHC-World, Woodstock,
MD) following the manufacturer’s protocol. The primary antibodies anti-NLRP3, antiCaspase1, anti ASC2, and Gasdermin D (Santa Cruz biotechnology, Inc., CA and Abcam,
MA) and used at recommended dilutions. Species-specific anti-IgG secondary antibodies
conjugated with Alexa Fluor 488 and Alexa Fluor 633 (Invitrogen, California, USA) was
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used at 1:100 dilution. The sections were mounted in a ProLong gold antifade reagent with
DAPI (Life technologies, EU, OR). Images were taken under 20x objective using Olympus
BX51 microscope.
In vitro: After completion of the treatments under serum starved condition as the
aforementioned cell culture section, cells attached on coverslips were fixed using 10%
Neutral Buffer Saline. After washing the cells with PBS, containing 0.1% triton x (Sigma,
MO) the cells were blocked using 3% BSA, 0.2% Tween (Fisher, NJ), 10% FBS in PBS.
Cells were incubated with primary antibodies anti-NLRP3, anti-Caspase1, anti ASC2, and
Gasdermin D, followed by species specific Alexa Fluor 633 and 488 secondary antibodies.
The stained cells attached on the coverslips were mounted on slides using ProLong gold
antifade reagent with DAPI (Life technologies, EU, OR) and viewed under 40x oil
objective using Olympus BX51 microscope.
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels
in the mice liver tissue samples and mouse primary hepatic macrophages were measured
by real-time reverse transcription-polymerase chain reaction (qRTPCR). Total RNA was
isolated from liver tissues and mouse primary hepatic macrophages using TRIzol reagent
(Life Technologies, Carlsbad, CA). Trizol reagent is used to lyse the tissue, RNA extraction
and purification are carried out by using RNeasy mini kit columns (Qiagen, Valencia, CA)
following manufacturer’s protocol. 1µg of purified RNA was converted to cDNA by using
iScript cDNA synthesis kit (Bio-rad, Hercules, CA). Quantitative real-time reverse
transcription-polymerase chain reaction was performed with the gene specific primers
using CFX96 thermal cycler (Bio-Rad, Hercules, CA) and SsoAdvanced universal SYBR
Green supermix (Bio-Rad, Hercules, CA). Threshold Cycle (Ct) values for genes of interest
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were normalized against 18S (internal control) values in same sample. Reaction was carried
out in triplicates for each gene and each tissue sample. The relative fold change was
calculated by the 2-∆∆Ct method. The primer sequences for mouse and rat targets (Table
2)
Western Blotting: In the presence of phosphatase and protease inhibitors (Pierce,
Rockford, IL), 30 mg of each liver tissue or cells in monolayer was homogenized in 500
µl of RIPA buffer (Sigma Aldrich) by using dounce homogenizer. The homogenate was
centrifuged and the supernatant was collected for further experiments. 25 µg of each
protein sample was loaded on 4–12% bis-tris gradient gel (Invitrogen, California, USA)
for SDS PAGE. By using precut nitrocellulose/filter paper sandwiches (Bio-Rad
Laboratories Inc., California, USA) and Trans – Blot Turbo transfer system (Bio-Rad),
proteins were transferred to nitrocellulose membrane. Blots were blocked with 5% non-fat
milk solution. Primary antibody against HMGB1, β-actin, IL-1β, Caspase 1 (Abcam, MA)
were used at recommended dilutions and incubated overnight at 4ºC. Followed by species
specific secondary antibodies conjugated with HRP (Abcam, MA) for 1h at room
temperature. Pierce ECL Western Blotting substrate (Thermo Fisher Scientific Inc.,
Rockford, IL) was used. The blot was imaged using G:Box Chemi XX6 (Syngene imaging
systems) and subjected to densitometry analysis using Image J.
LDH Cytotoxicity colorimetric assay: Cells were seeded in 96 well cell culture plates
and treated as described earlier with 0.25% FBS in phenol red free DMEM (Corning, MA),
after treatment LDH release was measured using the LDH Cytotoxicity colorometric assay
(Biovision, CA) following manufacturer’s instructions.
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IL-1β Assay: After cells were treated as described earlier. The supernatant was collected
and concentrated using a 3kd cutoff filters (Thermo Scientific, MA). Equal volumes of
concentrated supernatant were used to measure IL-1β by the Quantikine ELISA mouse IL1β /IL-1F2 Immunoassay (R&D systems, MN) following manufacturer’s instruction.
Statistical Analyses: The statistical analysis was performed by analysis of variance
(ANOVA) which was followed by Bonferroni post-hoc correction for intergroup
comparisons *p<0.05 and #p<0.01 are considered statistically significant.
3.3 RESULTS
P2X7r knockout protects liver tissue against lobular inflammation and steatosis. To
study the effects of P2X7r on liver injury in a mouse model of NAFLD, C57BL6/J mice
were fed with high fat diet for 16 weeks. HFD-fed mice showed insulin and leptin
resistance, macrovesicular steatosis, inflammation and little or no fibrosis, a condition that
resemble most NAFLD patients. NAFLD mice had markedly increased lobular
inflammation as shown by hematoxylin eosin staining (Figure 3.1 A) and lipid droplets
(Figure 3.1 B) when compared to both an early time point with no significant steatosis (4
weeks of HFD) (DIO group) or lean controls (LC group) (Figure 3.1 C). Interestingly such
effects were far less pronounced in mice which had a knockout for the P2X7r gene although
treated like the NAFLD group. NAFLD mice showed significantly increased protein levels
of P2X7r in the liver with higher immunoreactivity in both hepatocytes and sinusoidal
spaces when compared to DIO or LC mice (P<0.05) (Figure 3.1 D, Figure 3.1 E), strongly
suggesting the role of P2X7r in progression of liver injury in NAFLD.
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Extended consumption of high fat diet leads to hepatic P2X7r activated NLRP3
inflammasome: There are many recent reports showing the role of NLRP3 inflammasome
in liver injury in an under lying condition of NAFLD (115-118). Interesting the NLRP3
inflammasome is assembled by stimulus received from P2X7r ion channels (119-121). To
study whether high fat diet could lead to inflammasome activation in the mice liver We
looked at the NLRP3 inflammasome sub-units at gene and protein levels by qRT-PCR and
Western blots. To show successful assembly of the Inflammasome complex we did colocalisation studies for NLRP3 with ASC2 and NLRP3 with caspase 1. Results showed
that there was an increase in gene expression for NLRP3 inflammasome components in the
NAFLD group compared to the DIO or LC groups and significantly lower in the P2X7r
KO group (Figure 3.2 A). There was increased co-localisation events for NLRP3 with
ASC2 and NLRP3 with Caspase 1 especially in the sinusoidal spaces indicating
inflammasome assembly and activation in the sinusoidal cells of the NAFLD mice, these
co-localization events were dramatically reduced in the P2X7r KO groups (Figure 3.2 B,
Figure 3.2 C). Since activated inflammasome leads to cleavage of procaspase 1 to the
mature caspase 1 we looked at Caspase 1 protein levels, which was significantly lower in
the P2X7r KO group compared to the NAFLD mice (Figure 3.2 D, Figure 3.2 E). Caspase
1 is responsible for cleavage of and translocation of Gasdermin D to the membrane forming
pores (122), Immunofluorescence images show higher immunoreactivity to Gasdermin D
in the NAFLD group compared to the P2X7r KO group (Figure 3.2 F). Together this data
suggests that P2X7r mediation is important for NLRP3 inflammasome assembly and
downstream pyroptosis in the liver of NAFLD mice.
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P2X7r mediates HMGB1 release from fatty liver in NAFLD: Recent reports have
shown that pyroptosis is an innate immue function where it could lead to inflammation
(123, 124), however in metabolic diseases such as NAFLD, this inflammation is unchecked
and systemic. New reports suggest the role of pyroptosis in damage associated molecular
pattern, HMGB1 release inducing systemic inflammation in endotoxemia (125, 126). To
study whether HMGB1 was indeed being released by the liver in NAFLD by P2X7r
stimulation, we looked at the mRNA and protein levels of HMGB1 in liver tissue and
serum by qRT-PCR and Western blots. Results showed an increase in mRNA expression
of HMGB1 in NAFLD liver which was markedly decreased (P<0.05) in the P2X7r KO
(Figure 3.3 A), this data was further supported by HMGB1 protein levels in the tissue
(Figure 3.3 B, Figure 3.3 C). Interestingly stable HMGB1 levels were also found in the
serum (Figure 3.3 D, Figure 3.3 E) in the NAFLD mice, and this was also lowered in P2X7r
KO mice establishing that P2X7r mediated pyroptosis is responsible for systemic HMGB1
release.
P2X7r mediated NLRP3 inflammasome leads to pyroptosis and HMGB1 release in
Kupffer cells: Innate immune cells such as macrophages, dendritic cells have known to
release pro-inflammatory cytokines such as IL-1β and various DAMP’s including
HMGB1. One of the classical features of NLRP3 inflammasome activation is caspase1
mediated IL-1β release (114). There are many reports of macrophages undergoing
pyroptosis due to stressed conditions and infection leading to inflammation and DAMP
release (127-130). To establish macrophages released HMGB1 due to P2X7r mediated
pyroptosis, we treated the Kupffer cells with LPS an inducer of the NLRP3 subunits as
well as P2X7r Ag or An. Results showed that there was a significant decrease in the mRNA
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levels of the different NLRP3 inflammasome subunits ASC-2, NLRP3, Caspase 1 as well
as downstream effectors IL-1β and IL-18 in the P7 Ag treated cells which were lowered in
the P7 An treated group. (Figure 3.4 A). We also looked at NLRP3 inflammasome
formation due to P2X7r stimulation by co-localisation studies of NLRP3 with ASC2 and
Caspase1. P7 Ag stimulated cells showed higher co-localisation events compared to both
the control as well the P7 An treated groups (Figure 3.4 B, Figure 3.4 C) Along with
successful inflammasome activation, Caspase 1 protein levels were higher in the P7 Ag
groups compared to the control and P7 An treated groups (Figure 3.4 D, Figure 3.4 E).
Gasdermin D membrane translocation due to P7 Ag was ascertained by co-localising it
with VEGF-R a membrane receptor; P7 stimulation could recruit more Gasdermin D to the
membrane (Figure 3.4 F). Pyroptosis was also ascertained by looking at the levels of
released LDH1 from the P7Ag and An treated cells, the levels of LDH1 increased with
P2X7r stimulation and was significantly lowered (P<0.05) in cells treated with the P7
antagonist (Fig 3.4 G).
P2X7r mediates IL-1β and HMGB1 release in hepatic macrophages in Nonalcoholic
fatty liver disease: NAFLD is associated with the activation of resident macrophages in
the liver (57). They mediate their immunological effects by generation of reactive oxygen
species and release of pro-inflommatory cytokines which play a significant role in the
inflammation of the liver. We explored the possibility of P2X7r to release IL-1β and
HMGB1 from activated Kupffer cells by studying immunoreactivity of macrophage
activation markers CD68 and Monocyte chemoattractant protein (MCP-1) and IL-1β and
HMGB1 in the fatty liver, our results show that there was tremendous increase in the
immunoreactivity for CD-68 and MCP-1 in the NAFLD group (Figure 3.5 A, Figure 3.5
54

B) compared to the LC or the DIO group, while much less pronounced in the P2X7r KO
group. Interestingly immunoreactivity for HMGB1 and IL-1β also was abrogated in the
P2X7r KO groups (Figure 3.5 C, Figure 3.5 D) eluding to P2X7r as the mediator for
HMGB1 and IL-1β release in the macrophages. We then looked at HMGB1 and IL-1 β
production in Kupffer cells in-vitro, interestingly HMGB1 and IL-1 β levels were higher
in the supernatant of the cells treated with the P7 Ag compared to the Antagonist treated
cells (Figure 3.5 E, Figure 3.4 F).
3.4 DISCUSSION: The present study reports a novel mechanistic insight for HMGB1
release from Kupffer cells via P2X7r mediated NLRP3 inflammasome activated
pyroptosis. Using a rodent model of steatosis, we show that P2X7r stimulation could
assemble the NLRP3 inflammasome complex, further we show that this leads to Caspase
1 activation and membrane pore formation leading to IL-1β maturation and HMGB1
release. Toll like receptor 4 (TLR4) is activated in different inflammatory conditions. TLR4 signaling has been studied extensively in Non-alcoholic fatty liver disease (131-133). In
NAFLD there is an increase in gut permeability, allowing the leakage of bacterial
components (103). Portal endotoxemia from gut leaching has been accepted as a source for
TLR4 ligands in the liver (134, 135). TLR4 signaling leads to NFκB activation leading to
transcription of NLRP3, Pro-caspase 1 and Pro-IL1β increasing their cytosolic presence
(136-138). P2X7r mediatated K+ efflux leads to assembly of NLRP3 inflammasome subunits, bringing together NLRP3, adaptor protein ASC and pro-caspase 1. ASC binds to
many subunits of pro-caspase 1 bringing them near one another. Procaspase 1 cleaves each
other to release active caspase 1. Active caspase 1 is then able to cleave pro-IL-1β and proIL-18 to active IL-1β and IL-18 (120, 139). Caspase 1 also can cleave gasdermin D, leading
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to its membrane translocation where they polymerize and form membrane pores releasing
pro-inflammatory cytokines (140). Reports have shown that macrophages are able to
release HMGB1, a damage associated molecular pattern under conditions of stress (141,
142). Our data shows that there is an increase in circulating HMGB1 levels in the serum of
NAFLD mice, using in-vivo and in-vitro studies we have shown that HMGB1 release from
hepatic macrophages is mediated by the NLRP3 inflammasome formation and is dependent
on P2X7r stimulation.
NAFLD mice showed increased lobular inflammation and lipid accumulation
compared to lean control and an early NAFLD group, interestingly although treated like
the NAFLD mice, P2X7r KO mice did not show extensive damage as seen in the NAFLD
mice. Interestingly P2X7r activation increased in the liver tissue with the period of high fat
diet exposure with lean control mice having little to no P2X7r expression and NAFLD
group expressing P2X7r in the hepatocytes and the sinusoidal spaces. These results are
consistent with our previous findings of P2X7r activation in NAFLD/NASH progression
(24, 30).
We wished to explore the mechanism of action of P2X7r induced damage in fatty
liver. P2X7r is known to play a role in inflammation (143) and inflammasome formation
(134-141). Liver sections from NAFLD mice showed an increase in the mRNA levels of
the different sub-units of the NLRP3 inflammasome along with successful formation of the
NLRP3 inflammasome. Along with successful inflammasome assembly we also saw an
increase in active caspase 1 and gasdermin D expression in the NAFLD mice. Interestingly
all these effects were completely abrogated in the P2X7r KO mice indicating strong role
of P2X7r activated NLRP3 inflammasome assembly in NAFLD.
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Gasdermin D is cleaved by Caspase 1 resulting in its membrane translocation where
it can form pores releasing pro-inflammatory cytokines such as HMGB1 (140). NAFLD
mice had high levels of circulating HMGB1 in the serum, this increased presence of serum
HMGB1 is dependent on the duration of high fat diet and the presence of the P2X7r
receptor. HMGB1 is a multifunctional protein depending on its location. In the nucleus, it
distorts the DNA to allow transcription factors to bind to DNA easing transcription,
extracellularly it acts as a delayed regulator of inflammation released after much later than
the classical pro-inflammatory markers such as IL-1β, TNF-α, etc. HMGB1 mediates its
actions in two prominent ways binding to TLR4 a common receptor on immune cells or by
binding to RAGE, a receptor present in low levels in almost all cells (144, 145). Thus,
implying that HMGB1 release could indeed lead to systemic inflammation once in
circulation.
Since HMGB1 can cause systemic inflammation in chronic metabolic disorders it
is imperative to find out the mechanisms for its release from the liver in an underlying
condition of NAFLD. Since macrophages secrete HMGB1 under stress and we observed
NLRP3 inflammasome assembly in the sinusoidal spaces, we explored the possibility of
Kupffer cell HMGB1 release mediated by P2X7r activated NLRP3 inflammasome
formation. NLRP3 inflammasome is mediated by two signals. First TLR-4 receptors are
activated by bacterial LPS due to portal endotoxemia caused by gut leaching. This leads to
transcription and cytosolic buildup of NLRP3 inflammasome components and its effectors
pro-caspase1, pro-IL-1β. In-vitro treatment of Kupffer cells with LPS and P2X7r
stimulation led to increase in the NLRP3 sub-units, however treatment with both is required
for NLRP3 inflammasome assembly. Activated inflammasome leads to release of mature
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caspase 1. Caspase 1 then leads to Gasdemin D membrane translocation leading to release
of Lactose dehydrogenase (LDH1) a commonly found cytosolic protein. Interestingly all
these effects were abolished when the cells were treated with a P2X7r antagonist along
with LPS and P2X7r agonist, establishing role of P2X7r in NLRP3 inflammasome
mediated pyroptosis in Kupffer cells.
Since Kupffer cell activation is a prime inflammatory event in NAFLD, we
examined the levels of CD68 and MCP-1 (57, 146). Results showed a dramatic increase in
the levels of MCP-1 and surface expression of CD68 in the sinusoidal cells in the NAFLD
mice and significantly lower in the P2X7r KO mice. LPS and P2X7r stimulated Kupffer
cells were also able to release IL-1β and HMGB1 which was blunted using P2X7r
antagonists. Taken together, our data describes a novel mechanism of HMGB1 release
mediated by P2X7r activated NLRP3 inflammasome in hepatic macrophages in NAFLD.
Future studies looking at the effects of the released HMGB1 on distant organs will give us
a better idea of the systemic effects of NAFLD. Since we also see remediation of
inflammation by antagonizing the P2X7r channel, future studies looking at P2X7r
antagonists in remediation of macrophage mediated inflammation in NAFLD may lead to
interesting therapeutic regimen in NAFLD.
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Figure 3.1 P2X7r knockout protects liver tissue against lobular inflammation and steatosis.
A: hematoxylin and eosin-stained paraffin-embedded liver tissue sections of Lean Control
(LC), Early NAFLD (DIO), NAFLD and P2X7r KO. B: Oil redo stained frozen liver
sections LC, DIO, NAFLD and P2X7r KO. C. CRN NASH scores for LC, DIO, NAFLD
and P2X7r KO. D. P2X7r immunoreactivity as shown by immunohistochemistry in liver
slices from LC, DIO, NAFLD and P2X7r KO mice.
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Figure 3.2 Extended consumption of high fat diet leads to hepatic P2X7r activated NLRP3
inflammasome. A: qRT-PCR analysis of mRNA expression of NLRP3, ASC2, IL-18,
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Caspase 1 and IL-1β, and IL-23 from liver homogenates of LC, DIO, NAFLD and P2X7r
KO mice, normalized against LC (*P < 0.05). B: Immunofluorescence dual labeling
depicting NLRP3 (red)-ASC2 (green) colocalization (yellow) in LC, DIO, NAFLD and
P2X7r KO mouse samples. Images were taken at ×20 magnification. C:
Immunofluorescence dual labeling depicting NLRP3 (red)-Caspase 1 (green)
colocalization (yellow) in LC, DIO, NAFLD and P2X7r KO mouse samples. Images were
taken at ×20 magnification. D. Western blot analysis of Caspase 1 and β-actin protein levels
from liver homogenates of LC, DIO, NAFLD and P2X7r KO mice. E: Immunoreactive
band analysis of Caspase 1 normalized against β-actin (*P<0.05). F. Immunofluorescence
depicting Gasdermin D (red) in LC, DIO, NAFLD and P2X7r KO mouse samples.

Figure 3.3 P2X7r mediates HMGB1 release from fatty liver in NAFLD. A. qRT-PCR
analysis of mRNA expression of HMGB1 from liver homogenates of LC, DIO, NAFLD
and P2X7r KO mice, normalized against LC (*P < 0.05). B. Western blot analysis of
HMGB1 protein levels from serum samples of LC, DIO, NAFLD and P2X7r KO mice. C.
Western blot analysis of HMGB1 and β-actin protein levels from liver homogenates of LC,
DIO, NAFLD and P2X7r KO mice. D. Morphometric analysis of HMGB1
immunoreactivity in LC, DIO, NAFLD and P2X7r KO (*P < 0.05)
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Figure 3.4. P2X7r mediated NLRP3 inflammasome leads to pyroptosis and HMGB1
release in Kupffer cells A: qRT-PCR analysis of mRNA expression of NLRP3, ASC2, IL1β, IL-18 from Kupffer cells untreated ctrl, LPS, LPS+P7 Ag (P7Ag) and
LPS+P7Ag+P7An (P7An) normalized against Ctrl (*P < 0.05). B: Immunofluorescence
dual labeling depicting NLRP3 (red)-ASC2 (green) colocalization (yellow) in Ctrl, LPS,
P7 Ag and P7 An treated groups. Images were taken at ×40 magnification. C.
Immunofluorescence dual labeling depicting NLRP3 (red)-Caspase 1 (green)
colocalization (yellow) in Ctrl, LPS, P7 Ag and P7 An treated groups. Images were taken
at ×40 magnification. D. Western blot analysis of Caspase 1 and β-actin protein levels from
Ctrl, LPS, P7 Ag and P7 An treated groups. E. Morphometric analysis of Caspase 1
immunoreactivity in Ctrl, LPS, P7 Ag and P7 An treated groups (*P < 0.05). F.
Immunofluorescence dual labeling depicting Gasdermin D (red)- VEGF-R (green)
colocalization (yellow) in Ctrl, LPS, P7 Ag and P7 An treated groups. Images were taken
at ×40 magnification. G. Released LDH levels of Kupffer cells treated with Ctrl, LPS, P7
Ag and P7 An (*P < 0.05).

Figure 3.5: P2X7r mediates IL-1β and HMGB1 release in hepatic macrophages in
Nonalcoholic fatty liver disease.
A. CD-68 immunoreactivity as shown by
immunohistochemistry in liver slices from LC, DIO, NAFLD and P2X7r KO mice. B.
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MCP-1 immunoreactivity as shown by immunohistochemistry in liver slices from LC,
DIO, NAFLD and P2X7r KO mice. C. HMGB1 immunoreactivity as shown by
immunohistochemistry in liver slices from LC, DIO, NAFLD and P2X7r KO mice. D. IL1β immunoreactivity as shown by immunohistochemistry in liver slices from LC, DIO,
NAFLD and P2X7r KO mice.

Figure 3.5. E: Western blot analysis of HMGB1protein levels from supernatant of Kupffer
cells treated with Ctrl, LPS, P7 Ag and P7 An. F: IL-1β levels from supernatant of Kupffer
cells treated with Ctrl, LPS, P7 Ag and P7 An.

Table 3.1: Table showing the primer sequences for the different targets used in this
study.
Target
HMGB1 F
HMGB1 R
NLRP3 F
NLRP3 R
IL-1β F
IL-1β R
ASC-2 F
ASC-2 R
Caspase 1 F
Caspase 1 R
IL-18 F
IL-18 R
18S F
18S R

Sequence 5’-3’
GGACTCTCCTTTAACCGC
TTGTGATAGCCTTCGCTGGG
GACACGAGTCCTGGTGACTTT
GCCATGGAAGAAAAGTTCCTCTG
CCTCGGCCAAGACAGGTCGC
TGCCCATCAGAGGCAAGGAGGA
CACTCATTGCCAGGGTCACA
CACGAACTGCCTGGTACTGT
TGGTCTTGTGACTTGGAGGA
TGGCTTCTTATTGGCACGAT
AGGCCTGACATCTTCTGCAAC
CATTGTTCCTGGGCCAAGAGG
TTCGAACGTCTGCCCTATCAA
ATGGTAGGCACGGCGATA

Species
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
Mus Musculus
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IL-1β F
IL-1β R
IL-18 F
IL-18 R
NLRP3 F
NLRP3 R
ASC-2 F
ASC-2 R
18S F
18S R

Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus
Rattus Norvegicus

CCCTGCAGCTGGAGAGTGTGG
TGTGCTCTGCTTGAGAGGTGCT
ACACCACAAAACCTCAGCCA
AGGGACTTGAAACCAGAGCC
GGTGACCTTGTGTGTGCTTG
ATGTCCTGAGCCATGGAAGC
GGACAGTACCAGGCAGTTCG
TTCTTGCAGGTCAGGTTCCA
GGATCCATTGGAGGGCAAGT
ACGAGCTTTTTAACTGCAGCAA
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CHAPTER 4
HMGB1-RAGE PATHWAY DRIVES PEROXYNITRITE SIGNALING
INDUCED IBD-LIKE INFLAMMATION IN MURINE NONALCOHOLIC FATTY LIVER DISEASE.3

3

Chandrashekaran V, Seth RK, Dattaroy D, Alhasson F, Ziolenka J, Carson J, Berger FG,
Kalyanaraman B, Diehl AM and Chatterjee S. HMGB1-RAGE pathway drives
peroxynitrite signaling induced IBD like inflammation in murine Non-alcoholic fatty liver
disease. Redox Biol. 2017 Oct;13:8-19..
Reprinted here with the permission of the publisher.
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Abstract:
Recent clinical studies found a strong association of colonic inflammation and
Inflammatory bowel disease (IBD)-like phenotype with Non Alcoholic Fatty liver Disease
(NAFLD) yet the mechanisms remain unknown. The present study identifies high mobility
group box1 (HMGB1) as a key mediator of intestinal inflammation in NAFLD and outlines
a detailed redox signaling mechanism for such a pathway. NAFLD mice showed liver
damage and release of elevated HMGB1 in systemic circulation and increased intestinal
tyrosine nitration that was dependent on NADPH oxidase. Intestines from NAFLD mice
showed higher Toll like receptor 4 (TLR4) activation and proinflammatory cytokine
release, an outcome strongly dependent on the existence of NAFLD pathology and
NADPH oxidase. Mechanistically intestinal epithelial cells showed the HMGB1 activation
of TLR-4 was both NADPH oxidase and peroxynitrite dependent with the latter being
formed by the activation of NADPH oxidase. Proinflammatory cytokine production was
significantly blocked by the specific peroxynitrite scavenger phenyl boronic acid (FBA),
AKT inhibition and NADPH oxidase inhibitor Apocynin suggesting NADPH oxidasedependent peroxynitrite is a key mediator in TLR-4 activation and cytokine release via an
AKT dependent pathway. Studies to ascertain the mechanism of HMGB1-mediatied
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NADPH oxidase activation showed a distinct role of Receptor for advanced glycation end
products (RAGE) as the use of inhibitors targeted against RAGE or use of deformed
HMGB1 protein prevented NADPH oxidase activation, peroxynitrite formation, TLR4
activation and finally cytokine release. Thus, in conclusion the present study identifies a
novel role of HMGB1 mediated inflammatory pathway that is RAGE and redox signaling
dependent and helps promote ectopic intestinal inflammation in NAFLD.
4.1 INTRODUCTION
Recent clinical reports suggest intestinal inflammation, Inflammatory bowel disease-like
phenotype (IBD) and neoplasia in NAFLD cases (147-149). These reports are in addition
to the comorbidities in cardiovascular system associated with fatty liver disease (150).
Emerging data have highlighted the co-existence of non-alcoholic fatty liver disease
(NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent
disorders with significant complications and impact on future health burden (147). With
colorectal cancer the second leading cause of morbidity and mortality, the clinical finding
of colonic inflammation and neoplasia in NAFLD is very significant (149, 151). The report
also finds the association between nonalcoholic steatohepatitis, the active form of NAFLD
and colorectal neoplasms to be independent of demographics and metabolic factors (149).
Although reports of a strong intestinal inflammatory phenotype in NAFLD/NASH cases
and a mutual co-existence of liver inflammation in inflammatory bowel disease exist, the
cause of such ectopic manifestation remain poorly understood (147).
NAFLD has been shown to increase circulatory levels of cytokines including
adipokine leptin in the circulation, with the latter being proinflammatory in nature (57).
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However, evidence of leptin resistance due to the attenuation of the JAK/STAT signaling
pathway in peripheral tissues dampen its profound role in the intestine (152, 153). Recent
reports of other soluble molecular mediators of inflammation in NAFLD have emerged.
These include several damage associated molecular patterns like HMGB1, uric acid,
extracellular ATP and NAD and has been found to be prime causes of sterile inflammation
in the liver and other peripheral organs (104, 154-161).
NAFLD/ NASH have often been associated with hepatocyte necrosis primarily
from abnormal triglyceride metabolism and resultant lipotoxicity (162). Further, there is a
tight link between JNK1-dependent HMGB1 secretion from lipotoxic hepatocytes and a
paracrine cytolytic effect on neighboring cholesterol-loaded hepatocytes operating via
TLR4 (162). Interestingly HMGB1 can bind to TLR4 and generate a similar inflammatory
response though the binding of lipopolysaccharide is preferred over HMGB1 (163).
High mobility group box 1 (HMGB1) is a non-histone protein involved in
maintaining the architecture of chromatin. HMGB1 also acts extracellularly as a cytokine,
in processes such as inflammation, cell migration and stem cell recruitment. Plasma
HMGB1 level at admission is an indicator of the severity of illness and a useful mortality
predictor in exertional heatstroke (164). HMGB1 circulatory levels have been predictors
of outcome in neuroinflammation, ischemia reperfusion injury and sepsis (156, 165-169).
We and others have shown that HMGB1 circulatory levels are increased in NASH and are
found to contribute in the pathology of liver lobule and tubular toxicity (156, 159).
Though circulatory levels of HMGB1 has been associated with pathology, the
signaling pathways, its association with pattern recognition receptors in the intestine
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following liver injury has never been explored. HMGB1 can bind to both TLR4 and RAGE
and has been extensively reviewed by Weber et. al (163). Their binding abilities depend on
the redox states of HMGB1 (163). The reduced form contains a thiol group at all three
cysteine residues with a serum half-life of 17 min. It is this form that can bind to RAGE
and activate inflammatory pathways (163). The present study tested the hypothesis that
NAFLD leads to an increase in circulatory HMGB1 levels triggering inflammatory
pathways in the intestine. Mechanistically HMGB1 binds to RAGE in the distal intestine
and activates TLR4 translocation to lipid rafts via a peroxynitrite dependent manner. The
study reports a novel redox-immune crosstalk in a murine model of NAFLD and helps
understand a possible complicated relationship of innate immune interaction in NAFLDinduced ectopic intestinal inflammation and IBD-like phenotype.

4.2 MATERIALS AND METHODS
Animal model
Mice model for NAFLD
Pathogen-free, adult, male mice with C57BL/6J background (Jackson Laboratories, Bar
Harbor, ME) were used in the study. They were fed with a high-fat diet (60% kcal fat)
(Research diets, New Brunswich, NJ) for 18 wk was used as a model of nonalcoholic fatty
liver disease (NAFLD). Mice kept on a similar diet for 4 weeks served as a model for early
NAFLD (DIO), normal chow diet was used as a model of lean controls. Mice that contained
the disrupted p47 phox (B6.129S2-Ncf1tm1shl N14) (Taconic, Cranbury, NJ) gene were
treated similar to the NAFLD group. The animals were housed one in each cage before any
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experimental use. All groups of mice had ad libitum access to food and water and were
housed in a temperature-controlled room at 23–24°C with a 12-h:12-h light/dark cycle. All
animals were treated in strict accordance with the NIH Guide for the Humane Care and
Use of Laboratory Animals, and the experiments were approved by the institutional review
boards at NIEHS, Duke University, and the University of South Carolina at Columbia.
Immunohistochemistry
Formalin-fixed, paraffin-embedded liver and intestine tissue from all the mice groups were
cut into 5 μm thick tissue sections. Each section was deparaffinized using standard
protocol. Briefly, sections were incubated with xylene twice for 3 min, washed with
xylene:ethanol (1:1) for 3 min, and rehydrated through a series of ethanol (twice with
100%, 95%, 70%, 50%), twice with distilled water, and finally rinsed twice with PBS
(Sigma-Aldrich). Epitope retrieval of deparaffinized sections was carried out using epitope
retrieval solution and steamer (IHC-World, Woodstock, - MD) following the
manufacturer's protocol. The primary antibodies anti-HMGB1 (ab11354), anti-MCP-1
(ab7202), anti-TGF-β (ab170874), anti-IL1β (ab9722) and anti IFN-γ (ab24979) were
purchased from Abcam (Cambridge, MA) and used in 1:250 dilutions. Antigen-specific
immunohistochemistry was performed using Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine
(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by
Mayer's hematoxylin (Sigma-Aldrich. Sections were mounted in simpo mount (GBI
Laboratories, Mukilteo, WA) and observed under a 20X objective. Morphometric analysis
was done using CellSens Software from Olympus America.
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Quantitative RT-PCR
Gene expression levels in tissue samples were measured by two-step qRT-PCR. Total RNA
was isolated from liver and intestine tissue and cells grown in a monolayer by
homogenization in TRIzol reagent (Invitrogen) according to the manufacturer's
instructions and purified with the use of RNeasy mini kit columns (Qiagen, Valencia, CA).
Purified RNA (1 μg) was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad)
following the manufacturer's standard protocol. qRT-PCR was performed with the genespecific primers using SsoAdvanced SYBR Green supermix (Bio-Rad) and CFX96 thermal
cycler (Bio-Rad). Threshold Cycle (Ct) values for the selected genes were normalized
against 18S (internal control) values in the same sample. Each reaction was carried out in
triplicate for each gene and for each tissue sample. NAFLD mouse liver sample was used
as the control for comparison with all other liver samples form study groups of mice. The
relative fold change was calculated by the 2−ΔΔCt method.

Western Blot
Tissue (30 mg) from each liver sample was homogenized in 500 μl of RIPA buffer (SigmaAldrich) with protease inhibitor (1X) (Pierce, Rockford, IL) using dounce homogenizer.
For cells growing in monolayer were harvested using 0.05% Trypsin-EDTA (Gibco) and
lysed in MPER lysis buffer (100µL) (Thermo-Scientific). The lysate was sonicated using
the branson ultrasound sonicator. The homogenate was centrifuged and supernatant used
for SDS PAGE western blotting. 30 µg of protein from each sample was loaded on Novex
(Invitrogen, Carlsbad, CA) 4–12% bis-tris gradient gel and run for completion of SDS
PAGE. Resolved proteins bands were transferred to nitrocellulose membrane using precut
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nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories, Hercules, CA) and TransBlot Turbo transfer system (Bio-Rad) in case of low molecular weight proteins and using
wet transfer module from Invitrogen in case of high molecular weight proteins. A solution
of 5% non-fat milk was used for blocking. Primary antibodies against HMGB1, p-AKT
(ab81283) and Total AKT (ab8805) (all were purchased from Abcam) were used at 1:1000
dilutions, and compatible horseradish peroxidase-conjugated secondary antibodies were
used at 1:6000 dilution. Pierce ECL Western Blotting substrate (Thermo Fisher Scientific,
Rockford, IL) was used as a chemical substrate for the HRP. The blot was imaged using
G:Box Chemi XX6 (Syngene imaging systems) and subjected to densitometry analysis
using Image J.
Cell culture
Immortalized rat intestinal epithelial cells (IEC-6) were purchased from ATCC (CRL1592) was maintained in high glucose Dulbelcos modified eagles medium (DMEM),
Corning (Tewksbury, MA) supplemented with 10% fetal bovine serum (FBS), Atlanta
biologicals (Norcross, GA) supplemented with 2mM glutamine, 0.1 U/ml Insulin, 100U/ml
Penicillin, and 100μg/ml streptomycin; Gibco (Grand Island, NY) at 37oC in a humidified
atmosphere of 5% CO2. The cells were then treated with recombinant rat HMGB1
(Mybiosource. San Diego, CA) 30ng/ml a cytokine mediator of inflammation released by
activated macrophages able to bind to ad activate RAGE & TLR4, Apocynin (SigmaAldrich) 100µM an inhibitor of NADPH oxidase activity and thus prevents production of
superoxide, RAGE antagonist (FPS-ZM1, Milipore, MA) 200 nM V-domain ligand
binding RAGE inhibitor, Peroxynitrite (Cayman Chem, Ann Arbor, MI) 300 µM a highly
reactive structural isomer of nitrate, , Phenyl Boronic Acid (FBA) (Sigma Aldrich) 100µM
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was used as a scavenger for Peroxynitrite, PI3K inhibitor (LY294002, Sigma Aldrich)
10µM as an inhibitor for AKT phosphorylation as required either separately or in
combinations. To study the role of HMGB1, HMGB1 was denatured by boiling it at 100oC
for 1h. All treatments were carried for a period of 48h before further processing.
Immunofluorescence
Treated and control IEC-6 cells were fixed in 10% Neutral buffered Formalin for 15 min
at room temperature (RT). They were then permeabilized in PBS with 0.1% Triton X
(PBSTx) for 10 min followed by blocking with PBS containing 10% fetal bovine serum,
3% bovine serum albumin and 0.2% Tween 20 for 1h, Tissues were deparaffinized as
described earlier followed by epitope retrieval. The tissues were blocked with 3% BSA and
0.05% Tween 20 for 1h followed by incubation in IHC-Tek Antibody diluent solution.
Tissues and cells were then incubated with primary antibodies P47-Phox (SantaCruz SC17845), GP-91 Phox (SantaCruz SC-5827) and 3-Nitro Tyrosine (Abcam ab110282), TLR4 (Abcam ab13556), Flotilin (SantaCruz SC-74566) (1:250) diluted in blocking buffer at
4˚C overnight. Cells were washed thrice in PBSTx for 10 min each. The cells and tissues
were then incubated with compatible AlexaFlour conjugated secondary antibodies (1:100)
from Invitrogen. (Grand Island, NY), followed by three washes in PBSTx for 10 min each.
Finally, the cells were mounted in Prolong gold antifade reagent with DAPI. Images were
taken under 40X and 60X objective using the Olympus BX51 microscope.
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Statistical analysis
All experiments were repeated three times with 3 mice per group (N = 3; data from each
group of mice was pooled). The statistical analysis was carried out by analysis of variance
(ANOVA) followed by the Bonferroni posthoc correction for intergroup comparisons.
Quantitative data from western blots as depicted by the relative intensity of the bands were
analyzed by performing a student’s t test.
4.3 RESULTS:
Increased circulatory HMGB1 in NAFLD correlates well with peroxynitrite
generation, TLR4 trafficking to lipid rafts and intestinal inflammation in a NOX2
dependent manner. To study the role of circulatory HMGB1 in NAFLD in intestinal
inflammation, mouse intestinal tissue was evaluated for the mechanism of ectopic
inflammation. Results showed that there was a significant increase in the levels of MCP-1,
TGF-β, IL1β and IFN-γ when assessed by immunohistochemistry in the NAFLD group
when compared to both LC and DIO groups (Figure. 4.1 A). Further, mRNA levels of the
above cytokines increased significantly (p<0.001) in NAFLD group when compared to
both LC and DIO groups respectively suggesting the endogenous nature of the
inflammation (Figure. 4.1 B). Both increased levels of mRNA and protein of the cytokines
were significantly decreased (p<0.001) in p47 phox knockout mice when compared to
NAFLD mice suggesting that the inflammation was NOX-2 dependent (Figure. 4.1 A and
4. 1 B). To study whether NOX2 was activated in the small intestine, experiments were
performed to assess the membrane assembly of the NOX2 subunits p47 phox and gp91
phox using immunofluorescence microscopy and co-localisation studies. Results suggested
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that the number of colocalization events of gp91 phox and p47 phox in the intestinal
membrane were significantly higher in NAFLD group when compared to both LC and DIO
groups (Figure. 4.1 C and Figure. 4.1 D) while deletion of the p47 phox gene caused a
significant decrease in the membrane assembly (Figure. 4.1 C and Figure. 4.1 D)
suggesting a strong NOX2 activation in the NAFLD intestine. Since we have shown the
role of NOX2 in peroxynitrite formation in NAFLD, studies were conducted to show the
levels of 3-nitrotyrosine in the NAFLD intestine and whether the tyrosine nitration by
peroxynitrite was NOX-2 dependent. Results showed that there was a significant increase
in 3-nitrotyrosine levels in the NAFLD intestine group when compared to both LC and
DIO groups (Figure, 4.1 E and Figure. 4.1 F). 3-nitrotyrosine levels were significantly
decreased in the P47 phox knockout mice suggesting that the tyrosine nitration from
primarily peroxynitrite generation was NOX-2 dependent though other non-peroxynitrite
sources of 3-nitrotyrosine generation cannot be ruled out at this point (Figure. 4.1 E and
Figure 4.1 F). We have shown previously that NOX-2 drives TLR4 trafficking into the
lipid rafts (36). To study the role of NOX2 in TLR4 trafficking to lipid rafts and confirming
the role of NOX2-mediated TLR4 pathway in inflammation of the intestine, TLR4-Flotillin
colocalization were assessed in the NAFLD intestines. Results showed that the number of
TLR4-Flotillin colocalizations were significantly increased in the NAFLD intestines when
compared to both LC and DIO tissues (Figure. 4.1 G and Figure. 4.1 H) while there was a
significant decrease in the above colocalization events in the p47 phox knock mice
intestines suggesting a NOX-2 derived TLR4 trafficking (Figure. 4.1 G and Figure. 4.1 H).
NAFLD group also showed higher Claudin-2 protein levels, a hallmark of IBD-like
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phenotype when compared to lean and DIO groups (Figure. 4.1 I). P47 phox deletion
reversed the changes observed in Claudin-2 levels (Fig. 4.1 I).
HMGB1 primes NOX2 activation and TLR4-derived inflammation in intestinal
epithelial cells. To study the mechanism of HMGB1 induced NOX2 activation and
subsequent inflammation in the intestine, experiments were performed in intestinal
epithelial cells (IEC6). Results showed that cells primed with HMGB1 showed a significant
increase in p47 phox-gp91 colocalization events when compared to vehicle control (Fig.
4.2 A, Figure 4.2 B). HMGB1 primed cells treated with apocynin had significantly
decreased colocalization events when compared to HMGB1-only treatment (Figure. 4.2 A,
Figure. 4.2 B). HMGB1-primed cells had significantly higher immunoreactivity of tyrosine
nitration indicating a possible role of peroxynitrite that is NOX2 dependent when compared
to vehicle control and cells treated with apocynin (Figure. 4.2 C, Figure. 4.2 D). To confirm
the role of HMGB1 in NOX2 driven TLR4 trafficking, HMGB1 primed cells were assessed
for TLR4-Flotillin colocalization using immunofluorescence microscopy. Results showed
that HMGB1-primed cells had significant increase in TLR4-Flotillin colocalization events
when compared to vehicle control and apocynin treatment (Figure. 4.2 E, Figure 4.2 F).
The results suggested that HMGB1-mediated NOX2 was involved in TLR4 trafficking into
the lipid rafts, a crucial event that drives intestinal inflammation in NAFLD. TLR4
activation leads to an increase in the release of interleukins 1β and 6, that have been found
to have profound roles in intestinal inflammation and IBD-like phenotype (170). To study
whether HMGB1-activated NOX2 was involved in the release of IL1β and IL6, mRNA
expressions of these cytokines were assessed from cell lysates primed with HMGB1.
Results showed that HMGB1-primed cells had significantly increased IL1β and IL6
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mRNA expression when compared to vehicle control (p<0.001) and HMGB1-primed cells
treated with Apocynin (p<0.001) (Figure. 4.2 G and 4.2 H). The results suggested that
HMGB1-induced NOX2 activation increases expression of TLR4-pathway cytokines IL1β
and IL6.
Peroxynitrite drives TLR4 trafficking into lipid rafts via the AKT pathway. Results
obtained both invivo and invitro (Figure 4.1-4.2) suggested a possible role for NOX2
derived peroxynitrite in TLR4 activation and release of IL1β and IL6. To study the
involvement of peroxynitrite and its activation of AKT pathway for TLR4-trafficking into
the lipid rafts, experiments were designed in vitro to confirm this mechanism. Results
showed that cells primed with peroxynitrite caused a significant increase in TLR4-Flotillin
colocalization events when compared to vehicle control (Figure. 4.3 A, Figure. 4.3 B).
Cells primed with peroxynitrite but treated with specific peroxynitrite scavenger phenyl
boronic acid (FBA) showed a significant decrease in TLR4-Flotillin colocalization events
when compared to peroxynitrite-only primed cells (Figure. 4.3 A, Figure. 4.3 B). To show
the role of AKT in peroxynitrite-induced TLR4 trafficking into lipid rafts, cells were
treated with PI3K inhibitor. Results showed that peroxynitrite primed cells and PI3K
inhibitor showed a significant decrease in TLR4 trafficking into lipid rafts as indicated by
decreased TLR4-Flotillin colocalization events (Figure. 4.3 A, Figure. 4.3 B). To show that
peroxynitrite caused AKT phosphorylation in IE6 cells, experiments were performed to
study the phosphorylation in AKT and was compared to total AKT levels in the cell lysate.
Results showed that AKT phosphorylation peaked at 40 minutes post priming with
peroxynitrite (Figure. 4.3 C; Figure. 4.3 D). Thus, results from Figures. 4.3 A and 4.3 C
suggested a strong role of peroxynitrite-induced AKT phosphorylation in TLR4 activation
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a key event in IE6 cells. To study whether peroxynitrite-induced AKT phosphorylation and
TL4 activation was involved in the proinflammatory phenotype in intestinal epithelial cells,
mRNA expression of IL1β and IL6 were observed. Results showed that mRNA expression
of IL1β and IL6 were increased significantly (p<0.001) in peroxynitrite primed IE6 cells
when compared to vehicle controls (Figure. 4.3 E and Figure. 4.3 F). Cell treated with
peroxynitrite scavenger FBA or AKT inhibitor had significantly decreased (p<0.001)
expressions of IL1β and IL6 when compared to peroxynitrite-only group (Figure. 4.3 E and
Figure. 4.3 F).
HMGB1 binding to RAGE causes NOX2 activation and peroxynitrite generation. To
study the levels of RAGE in NAFLD intestines, qRTPCR was conducted from tissue
lysates. Results showed that NAFLD intestines showed a 35-fold increase in RAGE mRNA
expression when compared to lean controls (Figure. 4.4 A) and a >2-fold increase when
compared to DIO group (which does not show liver disease based on NASH scores).
Intestinal epithelial cells showed a significant increase in P47Phox expression (>5 fold)
when primed with HMGB1 but had significantly decreased P47Phox expression following
incubation with a specific RAGE-antagonist (Figure. 4.4 B). IE6 cells primed with
HMGB1 showed significantly increased gp91phox-p47 phox colocalization suggesting a
strong NOX2 activation when compared to vehicle controls (Figure. 4.4 C and Figure. 4.4
D). To ensure the specificity of HMGB1-RAGE binding we denatured the HMGB1 by
boiling the protein for 60 minutes. Also, we used a specific antagonist of RAGE as a dual
approach. Results showed that NOX2 activation was significantly inhibited using RAGE
antagonist and denatured HMGB1 as shown by decreased gp91-p47 phox colocalization
events (Figure. 4.4 C and Figure. 4.4 D). Tyrosine nitration which is a possible result from
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peroxynitrite dependent redox pathway was significantly increased in HMGB1-primed
cells when compared to vehicle controls (Figure. 4.4 E and Figure. 4.4 F). Incubation with
either a specific RAGE antagonist or use of denatured HMGB1 significantly decreased
tyrosine nitration when compared to HMGB1 primed cells (Figure. 4.4 E and Figure. 4.4
F) suggesting that HMGB1-RAGE binding was responsible for NOX2 activation and
peroxynitrite generation.
HMGB1 binding to RAGE causes TLR4 activation and proinflammatory cytokine
release. Following the results of HMGB1-RAGE activation of NOX2 and peroxynitrite
generation, it was imperative that we study the above pathway for TLR4 activation and
proinflammatory events in the intestinal cells. Results showed that HMGB1 primed cells
showed significant increase in TLR4-Flotillin colocalization that was blunted in the
presence of a specific RAGE antagonist and use of denatured HMGB1 (Figure. 4.5 A and
Figure. 4.5 B). Use of RAGE antagonist blunted TLR4 flotillin colocalization also implied
that HMGB1-binding to TLR4 was not a predominant pathway in the IE6 cells (Figure. 4.5
A). The significant (p<0.001) increase in IL1β and IL6 mRNA expression by IE6 cells
following HMGB1 priming was significantly decreased (p<0.001) using specific
antagonist against RAGE and the use of denatured HMGB1 suggesting that HMGB1RAGE binding was instrumental in proinflammatory cytokine expression (Figure. 4.5 C
and Figure. 4.5 D). Since monocyte chemoattractant protein (MCP1) also plays a role in
an inflammatory microenvironment, mRNA expression analysis of MCP1 was assayed in
IE6 cells. Results showed that MCP1 expression was significantly increased (p<0.001)
following HMGB1 priming (>40 fold) when compared to vehicle controls (Figure. 4.5 E).
Use of an antagonist for RAGE or use of denatured HMGB1 which has lost its binding
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ability to RAGE significantly (p<0.001) decreased expression of MCP1 mRNA suggesting
that

HMGB1-RAGE

interaction

increased

possibility

of

a

proinflammatory

microenvironment (Figure. 4.5 E).
4.4 DISCUSSION:
We present a novel pathological pathway of ectopic inflammation in the intestine following
development of progressive NAFLD that is mediated by a) circulatory HMGB1-RAGE
interaction and b) NOX2-Peroxynitrite-mediated TLR4 activation. The HMGB1-RAGEmediated NOX2 activation and subsequent peroxynitrite induced TLR4 trafficking into the
lipid rafts caused higher expression of IL1β and IL6 followed by increased release of MCP1, a chemokine known to attract neutrophils.
NAFLD and its progressive inflammatory phase nonalcoholic steatohepatitis has
been associated with intestinal inflammation resembling an IBD phenotype and colonic
neoplasia (149). Interestingly, steatosis or benign fat deposition in the liver was not found
to be associated with neoplasia (149). Our results where DIO group represented a benign
steatosis group showed no intestinal inflammation or cytokine release thus conforming to
the clinical data. This event may be ascribed to less HMGB1 in the liver and subsequent
decreased circulatory HMGB1 levels following decreased liver cell necrosis. Thus, a
progressive NAFLD with lobular inflammation as seen in our results paves way for higher
circulatory HMGB1 and is a ligand for a series of proinflammatory events in the intestinal
epithelial cells. The results also link the strong inflammatory phenotype observed in
NAFLD intestines in our studies.
Though a strong association was observed in patients with NAFLD/NASH to
development of colonic inflammation or studies that found NAFLD associations with IBD
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phenotype, the mechanisms that link these two inflammatory events were unclear (147,
149). Interestingly, there are considerable reports of circulatory cytokines, lack of
adiponectin or increased leptin in NAFLD that are proinflammatory in nature but a direct
mechanistic link to colonic inflammation is scarce (171). Our observation that high
circulatory HMGB1 in absence of significant other organ injuries probably originates in
the damaged liver bodes well for a prominent role of this DAMP in causing ectopic
intestinal inflammation. DAMPS has been found to play a prominent role in inflammation
in many diseases (172). However caution should be exercised when interpreting the data
since prolonged feeding with high fat diet has been associated with inflammatory lesions
in the intestine (173). Further the present study is limited in specifying the role of
circulatory HMGB1 in causing ectopic inflammation in the intestine since we have
unpublished data where intestinal HMGB1 was markedly increased following high fat
feeding though it was significantly less than the circulatory levels of HMGB1. Future
studies would have to focus on generating models that would clearly illustrate the source
of HMGB1. Sterile inflammation in the liver is found to be associated with HMGB1 and
other DAMPs (174). The above fact is supported by our results that show liver HMGB1
levels are significantly high in NAFLD and little or no HMGB1 protein levels were
detectable in the heart or kidney in our model of high fat fed mouse model of NAFLD.
HMGB1 is known for its proinflamamtory role in the intestine and other tissues including
liver (155, 174, 175). High circulatory levels of HMGB1 was associated with increased
expression of proinflammatory mediators IL1β, MCP1, TGF-β and IFN-γ (156, 176). High
HMGB1 was also associated with NOX2 activation and increased 3-nitro tyrosine
formation, a marker of peroxynitrite-mediated nitrative stress (177-179). The above events

82

decreased significantly in p47 phox knockout mice. Peroxynitrite formation and TLR4
trafficking to the lipid rafts also decreased in P47 phox knockout mice thus indicating that
the proinflammatory events including TLR4 trafficking was dependent on NOX2. This was
intriguing since HMGB1 is known to bind TLR4 in generating a proinflammatory cascade.
Our results also implied that if HMGB1 and redox signaling events were to generate an
inflammatory phenotype in the intestine, it had to do so by activating NOX2. Studies
suggest that HMGB1 can induce an activation of NOX2 by a Mac-1 dependent pathway
but in contrast can also induce phosphorylation of p40 subunit of NOX2, thereby inhibiting
its activation through a RAGE dependent pathway in neutrophils (38, 177). With HMGB1
levels being associated with increased NOX2 activation in the intestine we resorted to study
the redox pathway of inducing TLR4 signaling in our studies. Results showed that
HMGB1-primed intestinal epithelial cells activated NOX2, formed higher nitration of
tyrosine residues, increased TLR4 trafficking into lipid rafts and caused higher expression
of proinflammatory cytokines IL1β and IL6, events that were blocked by use of NOX2
inhibitor apocynin. Thus, HMGB1-NOX2 activation was upstream to TLR4 activation and
the results opened the possibility of a non-TLR4 based mechanism in our studies. Use of
AKT inhibitor also blocked peroxynitrite mediated TLR4 trafficking suggesting NOX2peroxynitrite-AKT signaling as a primary pathway for TLR4-mediated inflammation in the
intestinal epithelial cells.
RAGE has been found to bind HMGB1 in the B box binding region (163). The
three redox states of HMGB1 differ by structure, half-life, and activity. The redox states
determine the stability of HMGB1 and its binding to either RAGE or TLR4 (163). We
found higher RAGE expression in the NAFLD intestines. Our results also showed
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decreased

NOX2

activation,

peroxynitrite

formation,

TLR4

trafficking

and

proinflammatory mediator expression in RAGE antagonist treated HMGB1 primed
intestinal epithelial cells suggesting strongly that HMGB1 mediates its effect through
RAGE binding. Further the decreased and almost negligible TLR4 trafficking in the
presence of RAGE antagonist proved that HMGB1-RAGE binding but not HMGB1-TLR4
caused the inflammatory events in the cells. HMGB1 mediated effects were further
confirmed using denatured HMGB1 primed cells.
Though our results support strongly the involvement of circulatory HMGB1mediated inflammation in the NAFLD intestine, several questions remain unanswered.
Firstly, a high fat diet induced NAFLD model that we have used in the present study is a
slow and progressive inducer of liver disease pathology (38). Such models cause obesity
and insulin resistance and has been shown to alter gut microbiome and dysbiosis. It is
shown in clinical studies that dysbiosis is associated with IBD like phenotype which can
cause liver disease by itself (147, 171). This fact complicates our interpretation that
HMGB1 was primarily derived from liver and did not originate from the intestine. Most
murine models of NAFLD cause gut dysbiosis and there is hardly a way that a liver disease
phenotype is established where the intestine is unaffected. Secondly, HMGB1-TLR4
pathway is favored because of the increased stability of HMGB1 (163). This event does
not rule out the HMGB1-TLR4-mediated inflammation in other cell types of the intestine
since we studied the pathways only in the intestinal epithelial cells.
Taken together, our data in both an in vivo and in vitro setting shows a novel
HMGB1-RAGE mediated redox signaling pathway that exerts its effect through
peroxynitrite induced AKT phosphorylation which in turn directs TLR4 to lipid rafts (Fig.
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7). The ensuing event caused uninterrupted inflammation through release of IL1β, IL6 and
MCP1 and resulted in an IBD-like phenotype. With recent published studies including ours
showing the efficacy of specific peroxynitrite scavenger phenyl boronic acid (FBA) in
curbing NAFLD mediated inflammation, it will be justified to assume that FBA may be a
likely candidate for an interventional strategy to curb ectopic inflammatory events in
NAFLD or IBD itself (36). The present study also finds a probable mechanistic link to
NAFLD induced intestinal neoplasia since chronic inflammation such as that in NAFLD
is deemed to be paramount to such an event in humans.
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Figure 4.1. Increased circulatory HMGB1 in NAFLD correlates well with peroxynitrite
generation, TLR4 trafficking to lipid rafts and intestinal inflammation in a NOX2
dependent manner. A: Representative images of MCP-1, TGF-β, IL-1β and IFNγ
immunoreactivity as shown by immunohistochemistry in the intestinal sections of Lean
Control (LC), Early NAFLD (DIO), NAFLD and P47Phox KO mice taken at ×20
magnification. (*P < 0.05). B: qRT-PCR analysis of mRNA expression of MCP-1, TGFβ, IL-1β and IFN-γ from intestines of Lean Control (LC), Early NAFLD (DIO), NAFLD
and P47Phox KO mice. (*P < 0.05)
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Figure 4.1 C: Representative images for p47Phox (green) co-localisation with GP-91 Phox
(Red) as shown by immunofluorescence microscopy in the intestinal sections of Lean
Control (LC), Early NAFLD (DIO), NAFLD and P47Phox KO mice taken at 20x
magnification. (*P < 0.05). D: Morphometric analysis of p47Phox-GP-91Phox colocalisation (mean data from three separate microscopic fields were plotted on Y-axis) in
Lean Control (LC), Early NAFLD (DIO), NAFLD and p47Phox KO mice. E:
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Representative images of 3 Nitro-tyrosine immunoreactivity as shown by
immunofluorescence microscopy in the intestinal sections of (LC), (DIO), NAFLD and
P47Phox KO mice taken at 20x magnification. (*P < 0.05). F: Morphometric analysis of
3-Nitro-tyrosine immunofluorescence (mean data from three separate microscopic fields
were plotted on Y-axis) in LC, DIO, NAFLD and p47Phox KO mice. G: Representative
images for Flotilin (green) co-localisation with TLR-4 (Red) as shown by
immunofluorescence microscopy in the intestinal sections of (LC), (DIO), NAFLD and
P47Phox KO mice taken at ×20 magnification. (*P < 0.05). H: Morphometric analysis of
TLR-4-Flotilin co-localisation (mean data from three separate microscopic fields were
plotted on Y-axis) in LC, DIO, NAFLD and p47Phox KO mice. I: Representative images
of Claudin 2 immunoreactivity as shown by immunofluorescence microscopy in the
intestinal sections of (LC), (DIO), NAFLD and P47Phox KO mice taken at 20x
magnification. (*P < 0.05).
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Figure 4.2: HMGB1 primes NOX2 activation and TLR4-derived inflammation in intestinal
epithelial cells. A: Representative images for p47Phox (green) co-localisation with GP-91
Phox (Red) as shown by immunofluorescence microscopy in the intestinal epithelial cells
(IEC-6) treated with no treatment (Ctrl), HMGB1 or HMGB1 with NADPH oxidase
inhibitor Apocynin (HMGB1+Apo) at 40x magnification. (*P < 0.05). B: Morphometric
analysis of p47Phox-GP-91Phox co-localisation (mean data from three separate
microscopic fields were plotted on Y-axis) in IEC-6 cells untreated control or treated with
HMGB1 and HMGB1+Apocynin (HMGB1+Apo). C: Representative images of 3 Nitro89

tyrosine immunoreactivity as shown by immunofluorescence microscopy in IEC-6 cells
treated with Ctrl, HMGB1 or HMGB1+Apo at 40x magnification. (*P < 0.05). D:
Morphometric analysis of 3-Nitro-tyrosine immunofluorescence (mean data from three
separate microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or
treated with HMGB1 and HMGB1+Apo. E: Representative images for Flotilin (green) colocalisation with TLR-4 (Red) as shown by immunofluorescence microscopy IEC-6 cells
treated with Ctrl, HMGB1 or HMGB1+Apo at 40x magnification. (*P < 0.05). F:
Morphometric analysis of TLR-4-Flotilin co-localisation (mean data from three separate
microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or treated
with HMGB1 and HMGB1+Apo.

Figure 4.2 qRT-PCR analysis of mRNA expression of G: IL-1β and H:.IL-6 from IEC-6
cells treated with Ctrl, HMGB1 or HMGB1+Apo.
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Figure 4.3 Peroxynitrite drives TLR4 trafficking into lipid rafts via the AKT pathway. A:
Representative images for Flotilin (green) co-localisation with TLR-4 (Red) as shown by
immunofluorescence microscopy IEC-6 cells treated with no treatment (Ctrl), Peroxynitrite
(Peroxy), Peroxynitrite+Phenyl boronic acid (Peroxy+FBA) or Peroxynitrite+AKT
inhibitor (Peroxy+AKTi) (*P < 0.05). B: Morphometric analysis of TLR-4-Flotilin colocalisation (mean data from three separate microscopic fields were plotted on Y-axis) in
IEC-6 cells untreated control or treated with Peroxynitrite (Peroxy),
Peroxynitrite+Phenylboronic acid (Peroxy+FBA) and Peroxynitrite +AKT inhibitor
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(Peroxy+AKTi). C: Western blot analysis of p-AKT and Total AKT protein levels of IEC6 cells, Ctrl, Peroxy and Peroxy+FBA at 20 m time intervals (*P < 0.05). D: Morphometric
analysis of p-AKT immunoreactivity in IEC-6 cells untreated control or treated with
Peroxy and Peroxy+FBA for 20 min intervals. E: qRT-PCR analysis of mRNA expression
of IL-1β and F: IL-6 from IEC-6 cells treated with Ctrl, Peroxy and Peroxy+FBA and
Peroxy+AKTi (*P < 0.05).

Figure 4.4 HMGB1 binding to RAGE causes NOX2 activation and peroxynitrite
generation. A: qRT-PCR analysis of mRNA expression of RAGE from intestines of Lean
Control (LC), Early NAFLD (DIO), NAFLD mice. B: qRT-PCR analysis of mRNA
expression of p47Phox from IEC-6 cells treated with Ctrl, HMGB1 or HMGB1+RAGE
Antagonist (HMGB1+RAGE An). C: Representative images for p47Phox (green) colocalisation with GP-91 Phox (Red) as shown by immunofluorescence microscopy in the
intestinal epithelial cells (IEC-6) treated with no treatment (Ctrl), HMGB1 or
HMGB1+RAGE An and HMGB1 destroyed (des) at 40x magnification. (*P < 0.05). D:
Morphometric analysis of p47Phox-GP-91Phox co-localisation (mean data from three
separate microscopic fields were plotted on Y-axis) in IEC-6 cells untreated control or
treated with HMGB1, HMGB1+RAGE An and HMGB1 des.
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Figure 4.4 E: Representative images of 3 Nitro-tyrosine immunoreactivity as shown by
immunofluorescence microscopy in IEC-6 cells treated with Ctrl, HMGB1 or
HMGB1+RAGE An and HMGB1 des at 40x magnification. (*P < 0.05). F: Morphometric
analysis of 3-Nitro-tyrosine immunofluorescence (mean data from three separate
microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or treated
with HMGB1, HMGB1+RAGE An and HMGB1 des.

93

Figure 4.5. HMGB1 binding to RAGE causes TLR4 activation and proinflammatory
cytokine release. A: Representative images for Flotilin (green) co-localisation with TLR4 (Red) as shown by immunofluorescence microscopy IEC-6 cells treated with no
treatment (Ctrl), HMGB1, HMGB1+RAGE Antagonist (HMGB1+RAGE An) or
destroyed HMGB1 (HMGB1 des) (*P < 0.05). B: Morphometric analysis of TLR-4Flotilin co-localisation (mean data from three separate microscopic fields were plotted on
Y-axis) in IEC-6 cells untreated control or treated with HMGB1, HMGB1+RAGE An and
HMGB1 des. C: qRT-PCR analysis of mRNA expression of IL-1β, D: IL-6 and E: MCP1 from IEC-6 cells treated with Ctrl, HMGB1, HMGB1+RAGE An and HMGB1 des. (*P
<0.05).

Figure 4.6: A pictorial representation of the molecular process in liver HMGB-1-RAGE
mediated ectopic intestinal inflammation in murine NAFLD.
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Table 4.1: Table showing the primer sequences for the different targets used in this study.
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CHAPTER 5
CONCLUSION
Obesity has slowly become the public health problem of this century. More than two-thirds
of the adult American population is considered obese. Obesity is a complex disorder which
increases the chances of various physical diseases. Obesity is associated with a lot of
inflammatory metabolic disorders such as Non-alcoholic fatty liver disease (NAFLD).
NAFLD is a hepatic manifestation of metabolic syndrome which arises due to abnormal
fat (<5% of the liver weight) accumulation in liver. According to the widely recognized
“multiple hits” theory of NASH, the first hit due to accumulation of lipids in the liver make
it susceptible to secondary insults like oxidative stress, subsequent lipid peroxidation,
proinflamatory cytokines, adipokines and mitochondrial dysfunction. All these factors lead
to hepatic injury leading to inflammation and fibrosis which if unchecked can lead to liver
cirrhosis or hepatocellular cancer. The greatest problem with this disease is that it is largely
asymptomatic and the affected individuals feel normal and go undetected until the liver
undergoes tissue hardening and scarring. Previous studies from our group has shown that
chronic exposure to low doses of Bromo-dichloromethane (BDCM), a common water
disinfection byproduct is able to aggravate liver injury causing Non-alcoholic
steatohepatitis (NASH) where CYP2E1 mediated oxidative stress acts as the secondary hit
in obese mice. In the present study, I studied the molecular mechanisms by which Hepatic
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stellate cells, a group of fibroblastic liver cells can get activated in an underlying condition
of NASH induced by BDCM exposure, I also looked at how obesity is able to cause
systemic inflammation by release of pro-inflammatory mediators via pyroptosis from the
liver resident macrophage cells in-vivo and in-vitro models of NAFLD.
There are many reports of Hepatic stellate cell activation in the progression of
NAFLD/NASH (180-182), however the exact mechanism of the process is largely unclear.
Here, I investigated the role of Leptin mediated P2X7r stimulation leading to glucose
uptake via GLUT4 induction activating hepatic stellate cells (HSC’s) during NASH.
Human NASH liver samples and a high-fat (60% kcal) diet-fed BDCM induced mouse
NASH model were used for this study. Mice deficient in genes for leptin, and P2X7r were
used to prove the role of the leptin-P2X7r-GLUT4 axis. Our results showed that Leptin
was essential for significant activation of P2X7r channels wild-type (C57BL/6
background) mice NASH model and human NASH liver samples. These samples also
showed increased GLUT4, an important glucose transporter and α-SMA a marker of
activated HSC’s. mRNA and protein levels, interestingly GLUT4 was expressed in the
sinusoidal cells and was co-localized with α-SMA in both wild type mice NASH model
and human NASH liver samples. This increase in GLUT4 and α-SMA was remarkably
lowered in P2X7r or Leptin deficient mice indicating roles of both in activation of HSC’s
via glucose uptake. Since glucose levels in cells are tightly controlled by Insulin signaling
in cells which activates the AKT pathway, we looked at p-AKT levels in the NASH mice
and found that there was significant increase in the levels of p-AKT in the wild type NASH
mice with significantly lower levels in Leptin and P2X7r KO mice, indicating that they
may be able to control glucose levels via AKT activation. This was proved by treating the
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HSC’s in-vitro with specific P2X7r Agonists and P7 Antagonists in the presence or absence
of Leptin along with an AKT inhibitor. In-vitro experiments showed that Leptin could
stimulate P2X7r leading to AKT phosphorylation. AKT phosphorylation is necessary for
induction of GLUT4, and subsequent glucose import in the HSC’s. Increased glucose
levels lead to HSC activation in NASH. This was the first study that elucidates the role of
Leptin mediated P2X7r activation leading to GLUT4 induction activating HSC in a murine
and human NASH liver samples (24). This research opened an interesting mechanism for
HSC activation by Leptin-P2X7r-GLUT4 axis leading to hepatic injury. Thus, P2X7r can
be considered an important therapeutic target in the treatment of NASH.
Along with the mechanism for liver injury, I also explored the possibility of the
fatty liver being able to affect other organ systems, in this study I specifically looked at
how the NAFLD liver could affect the intestines. Although there are many reports
establishing the liver as the secondary metastatic site for intestinal cancers (183-187),
however very few studies have explored the possibility of the NAFLD liver able to cause
inflammation and cancer in the intestines. NAFLD liver can release a lot of Damage
associated molecular patterns (DAMP’s) from necrotic cells due to the oxidative stress and
severe inflammation. These DAMP’s can enter circulation and reach distant organs. We
were the first group to show that HMGB1, a DAMP is released through the hepatic resident
macrophage cells (Kupffer cells) by a process called pyroptosis, this HMGB1 released is
stable in circulation and can cause inflammation by binding to and activating RAGE
receptors in the intestines.
Previous studies have identified macrophages are able to release HMGB1 as a
proinflammatory cytokine (141, 188). Interestingly, I found that levels of HMGB1 was
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dramatically higher in serum from NAFLD mice and levels were significantly lower in the
P2X7r KO mice. mRNA and protein expression of HMGB1 co-related to the levels of
HMGB1 found in the serum. Concurrently we see an increase in Kupffer cell activation in
the liver evidenced by an increase in CD68 and monocyte chemoattractant protein 1
(MCP1) in the NAFLD liver which was lower in the P2X7r KO mice. Since P2X7r leads
to a unique form of cell death called pyroptosis by activating the NLRP3 inflammasome.
Mechanistically, using immortalized rat Kupffer cells and liver tissue from wild type and
P2X7r KO mice fed on a high fat diet, I have shown P2X7r stimulation is able to cause
HMGB1 release via pyroptosis by the NLRP3 inflammasome, as evidenced by the
membrane translocation of Gasdermin D and the co-localisation of NLRP3 with Caspase1
and ASC2. This along with the detection of HMGB1, LDH and IL-1β in the supernatant of
P2X7r stimulated cells confirms Pyroptosis due to P2X7r stimulation as a means for
systemic HMGB1 release in NAFLD.
HMGB1 extracellularly acts as a pro-inflammatory cytokine which mediates its
effects by binding to TLR-4 and RAGE. In this study I have shown HMGB1 preferentially
and selectively binds to RAGE receptors. Previous studies have shown that HMGB1RAGE binding is able to activate NOX2 enzyme complex (36, 179). We showed similar
results as evidenced by successful assembly of the NADPH oxidase complex at the cell
membrane. Also, a previous study by our group, showed that NADPH oxidase can recruit
TLR-4 to the lipid rafts of the cell membrane via peroxynitrite production (189). However,
the exact mechanism for the same is unknown. Using a p47Phox KO mice model treated
like the NAFLD group we showed that TLR-4 recruitment to lipid rafts is indeed dependent
on NADPH oxidase. Activated NADPH oxidase generates Peroxynitrite, which is a highly
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reactive compound which causes protein nitration, using immortalized rat intestinal
epithelial cells I have shown here that peroxynitrite can cause transient phosphorylation of
AKT, possibly by inactivating PTEN. Phosphorylated AKT is then able to recruit TLR-4
to the lipid rafts of the cell membrane. Once TLR-4 is recruited to the cell membrane it is
then able to bind to its ligands HMGB1 and LPS which are present in high levels in the
underlying conditions of NAFLD leading to release of inflammatory cytokines IL-1β and
IL6. Using a destroyed HMGB1 sample I showed that TLR-4 recruitment is dependent on
HMGB-1-RAGE binding as shown by decrease in TLR-4 co-localization with Flotilin in
the lipid rafts with use of either destroyed HMGB1 or RAGE An.
This study shows a novel mechanism for cross talk between the liver and the
intestines and sheds more light on the systemic damage that could be caused due to
NAFLD. Our group has also recently used a natural plant based product called Sparstolonin
B which is a potent TLR-4 antagonist, results from our group has shown to be a strong antiinflammatory and antifibrogenic pharmaceutical mediator (189-191). HMGB1 antibodies
have already being used as therapeutic interventions in brain injury and arthiritis (192,
193). This in combination with the use of RAGE antagonists or P2X7r inhibitors could
serve as an effective anti-inflammatory mediation in metabolic disorders such as NASH.
Although intervention strategies help in remediation of NAFLD, early detection is key as
these patients are largely asymptomatic. With the rates of obesity doubling every year. It
is imperative that public awareness about NAFLD and the impact it can have on human
health be raised. Periodic checkups for liver enzymes at individual and community level
should be encouraged for early diagnosis and remediation. The state can also help by
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encouraging healthy eating habits in schools and the community and building sidewalks
and playgrounds for citizens to adopt a healthy and active lifestyle.
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